Suchergebnisse - "олокизумаб"

Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real-world clinical practice in Kazakhstan

Autoren: G. A. Togizbayev D. I. Parpiyeva D. A. Maksot

Quelle: Современная ревматология, Vol 0, Iss 0 (2020)
Современная ревматология, Vol 19, Iss 3, Pp 74-79 (2025)

Schlagwörter: rheumatoid arthritis, safety, ингибиторы ил-6, olokizumab, interleukin-6 inhibitors, efficacy, ревматоидный артрит, эффективность, Medicine, безопасность, олокизумаб

Zugangs-URL: https://doaj.org/article/c8bb6939dfe24ce9b538ef35c3b23faf
https://doaj.org/article/47ac6c6034ad4f9a95d8b4045857fe92

The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study ; Влияние потенциально гепатотоксичных препаратов на активность аланиновой трансаминазы у пациентов с COVID-19: исследование «случай–контроль»

Autoren: V. I. Petrov A. Yu. Ryazanova N. S. Tokareva et al.

Weitere Verfasser: V. I. Petrov A. Yu. Ryazanova N. S. Tokareva et al.

Quelle: Safety and Risk of Pharmacotherapy; Online First ; Безопасность и риск фармакотерапии; Online First ; 2619-1164 ; 2312-7821 ; undefined

Schlagwörter: омепразол, RUCAM scale, COVID-19, matched case–control study, alanine transaminase, favipiravir, remdesivir, tocilizumab, olokizumab, levilimab, omeprazole, аланиновая трансаминаза, шкала RUCAM, исследование «случай–контроль», метод подбора пар, фавипиравир, ремдесивир, тоцилизумаб, олокизумаб, левилимаб

Dateibeschreibung: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/458/1310; https://www.risksafety.ru/jour/article/view/458/1311; https://www.risksafety.ru/jour/article/view/458/1312; https://www.risksafety.ru/jour/article/view/458/1315; https://www.risksafety.ru/jour/article/view/458/1316; https://www.risksafety.ru/jour/article/view/458/1318; https://www.risksafety.ru/jour/article/view/458/1319; https://www.risksafety.ru/jour/article/view/458/1320; https://www.risksafety.ru/jour/article/view/458/1324; https://www.risksafety.ru/jour/article/view/458/1326; https://www.risksafety.ru/jour/article/view/458/1328; https://www.risksafety.ru/jour/article/downloadSuppFile/458/556; https://www.risksafety.ru/jour/article/downloadSuppFile/458/612; https://www.risksafety.ru/jour/article/downloadSuppFile/458/613; https://www.risksafety.ru/jour/article/downloadSuppFile/458/614; https://www.risksafety.ru/jour/article/downloadSuppFile/458/619; https://www.risksafety.ru/jour/article/downloadSuppFile/458/620; https://www.risksafety.ru/jour/article/downloadSuppFile/458/621; https://www.risksafety.ru/jour/article/downloadSuppFile/458/622; https://www.risksafety.ru/jour/article/downloadSuppFile/458/623; https://www.risksafety.ru/jour/article/downloadSuppFile/458/625; Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature. BMC Med. 2016;14:10. https://doi.org/10.1186/s12916-016-0553-2; De Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: A population based case-control study. Br J Clin Pharmacol. 2004;58(1):71–80. https://doi.org/10.1111/j.1365-2125.2004.02133.x; Valenti L, Pelusi S, Bianco C, Ceriotti F, Berzuini A, Iogna Prat L, et al. Definition of healthy ranges for alanine aminotransferase levels: A 2021 update. Hepatol Commun. 2021;5(11):1824–32. https://doi.org/10.1002/hep4.1794; Schmilovitz-Weiss H, Gingold-Belfer R, Boltin D, Beloosesky Y, Meyerovitch J, Tor R, et al. Risk of mortality and level of serum alanine aminotransferase among community-dwelling elderly in Israel. Eur J Gastroenterol Hepatol. 2018;30(12):1428–33. https://doi.org/10.1097/MEG.0000000000001225; Jensen MD, Lauritzen T, Vilstrup H, Jepsen P. Alanine aminotransferase and 20-year risk of major chronic diseases and death in a healthy cohort aged 30 to 49 years. Clin Epidemiol. 2020;12:345–51. https://doi.org/10.2147/CLEP.S241292; Danan G, Teschke R. Drug-induced liver injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch? Drug Saf. 2018;41;735–43. https://doi.org/10.1007/s40264-018-0654-2; Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The update. Int J Mol Sci. 2015;17(1):14. https://doi.org/10.3390/ijms17010014; Bessone F, Dirchwolf M, Rodil MA, Razori MV, Roma MG. Review article: Drug-induced liver injury in the context of nonalcoholic fatty liver disease — a physiopathological and clinical integrated view. Aliment Pharmacol Ther. 2018;48(9):892–913. https://doi.org/10.1111/apt.14952; Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, et al. Consensus guidelines: Best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in adults with chronic viral hepatitis and adults with cirrhosis secondary to hepatitis B, C and nonalcoholic steatohepatitis. Drug Saf. 2021;44(2):133–65. https://doi.org/10.1007/s40264-020-01014-2; Жарова МЕ, Иваников ИО, Григорьева ЮВ, Никонов ЕЛ. Поражение печени у пациентов с COVID-19: клинико-патогенетические особенности и факторы риска. Доказательная гастроэнтерология. 2023;12(3):51–62. https://doi.org/10.17116/dokgastro20231203151; Петров ВИ, Пономарева АВ, Ивахненко ИВ, Разваляева ОВ, Мешрки БА, Стаценко ВИ. Этиопатогенетические аспекты повреждения печени у пациентов с COVID-19. Вестник Волгоградского государственного медицинского университета. 2020;17(4):9–15. https://doi.org/10.19163/1994-9480-2020-4(76)-9-15; Papagiouvanni I, Kotoulas SC, Pataka A, Spyratos DG, Porpodis K, Boutou AK, et al. COVID-19 and liver injury: an ongoing challenge. World J Gastroenterol. 2023;29(2):257–71. https://doi.org/10.3748/wjg.v29.i2.257; Li P, Liu Y, Cheng Z, Yu X, Li Y. COVID-19-associated liver injury: Clinical characteristics, pathophysiological mechanisms and treatment management. Biomed Pharmacother. 2022;154:113568. https://doi.org/10.1016/j.biopha.2022.113568; Teschke R, Méndez-Sánchez N, Eickhoff A. Liver injury in COVID-19 patients with drugs as causatives: A systematic review of 996 DILI cases published 2020/2021 based on RUCAM as causality assessment method. Int J Mol Sci. 2022;23(9):4828. https://doi.org/10.3390/ijms23094828; Muhović D, Bojović J, Bulatović A, Vukčević B, Ratković M, Lazović R, et al. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Liver Int. 2020;40(8):1901–5. https://doi.org/10.1111/liv.14516; Петров ВИ, Рязанова АЮ, Привальцева НС, Некрасов ДА. Полипрагмазия при лечении стационарных больных с новой коронавирусной инфекцией COVID-19. Фармация и фармакология. 2022;10(3):267–77. https://doi.org/10.19163/2307-9266-2022-10-3-267-277; Гржибовский АМ, Иванов СВ, Горбатова МА. Исследования типа «случай-контроль» в здравоохранении. Наука и здравоохранение. 2015;(4):5–17. EDN: VCFVUZ; https://www.risksafety.ru/jour/article/view/458

Verfügbarkeit: https://www.risksafety.ru/jour/article/view/458
https://doi.org/10.30895/2312-7821-2025-458

Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence ; Применение прямого ингибитора интерлейкина 6 олокизумаба в терапии ревматоидного артрита: данные реальной клинической практики

Autoren: P. A. Shesternya A. I. Zagrebneva O. V. Antipova et al.

Weitere Verfasser: P. A. Shesternya A. I. Zagrebneva O. V. Antipova et al.

Quelle: Modern Rheumatology Journal; Том 19, № 2 (2025); 39-49 ; Современная ревматология; Том 19, № 2 (2025); 39-49 ; 2310-158X ; 1996-7012

Schlagwörter: реальная клиническая практика, olokizumab, IL-6 inhibitor, real world evidence, олокизумаб, ингибитор интерлейкина 6

Dateibeschreibung: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1738/1582; Клинические рекомендации "Ревматоидный артрит". https://www.consultant.ru/document/cons_doc_LAW_495885/8efd5f17af55cb35a770f73937590c642437b7eb/; Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57. doi:10.1038/ni.3153.; Aletaha D, Kerschbaumer A, Kastrati K, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis. 2023 Jun;82(6):773-787. doi:10.1136/ard-2022-222784. Epub 2022 Aug 11.; Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? BioDrugs. 2024 Jan;38(1):61-71. doi:10.1007/s40259-023-00634-1. Epub 2023 Nov 21.; Насонов ЕЛ, Файст Е. Перспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6). Научно-практическая ревматология. 2022;60(5): 505-518.; https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f2bc77b4-6298-4b2e-8f37-18e1baa0b63c; http://publication.pravo.gov.ru/document/0001202309010013; Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008 Nov 15; 112(10):3959-64. doi:10.1182/blood-2008-05-155846. Epub 2008 Sep 10.; Kretsos K, Golor G, Jullion A, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi:10.1002/cpdd.121. Epub 2014 May 26.; Лапкина НА, Баранов АА, Левшин НЮ и др. Динамика клинических проявлений и концентрации цитокинов у больных ревматоидным артритом на фоне терапии олокизумабом. Научно-практическая ревматология. 2023;61(4):475-484.; Garrison LP Jr, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007 Sep-Oct;10(5):326-35. doi:10.1111/j.1524-4733.2007.00186.x.; Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. Guidance for Industry and Food and Drug Administration Staff, issued 31 August 2017. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/usereal-world-evidence-support-regulatory-decision-making-medical-devices; Гольдина ТА, Суворов НИ. Исследования рутинной клинической практики: от получения данных к оценке медицинских технологий и принятию решений в здравоохранении. Медицинские технологии. Оценка и выбор. 2018;(1):21-29.; Tony HP, Feist E, Aries PM, et al. Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany. Rheumatol Adv Pract. 2022 Feb 1;6(1):rkac002. doi:10.1093/rap/rkac002. eCollection 2022.; Emery P, van Hoogstraten H, Thanga velu K, et al. Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open-Label Extension of a Randomized Clinical Trial. ACR Open Rheumatol. 2020 Nov;2(11):672-680. doi:10.1002/acr2.11188. Epub 2020 Nov 8.; Загребнева АИ, Симонова ЕН, Мезенова ТВ и др. Московский опыт применении ингибиторов рецептора интерлейкина 6 в терапии ревматоидного артрита в условиях пандемии COVID-19. Современная ревматология. 2022;16(6):73-79. doi:10.14412/1996-7012-2022-6-73-79; Баранов АА, Виноградова ИБ, Аношенкова ОН и др. Ведение больных ревматоидным артритом в реальной клинической практике: опыт переключения с терапии ингибитором рецепторов интерлейкина 6 на прямой ингибитор интерлейкина 6 (олокизумаб). Научно-практическая ревматология. 2023;61(3):307-319.; Шестерня ПА, Баранов АА, Виноградова ИБ и др. Переключение с ингибиторов рецепторов интерлейкина 6 на прямой ингибитор интерлейкина 6 олокизумаб у пациентов с ревматоидным артритом: эффективность и безопасность в течение 1 года терапии. Современная ревматология. 2024;18(5):54-64. doi:10.14412/1996-7012-2024-5-54-64; England BR, Sayles H, Mikuls TR, et al. Validation of the rheumatic disease comorbi dity index. Arthritis Care Res (Hoboken). 2015 May;67(6):865-72. doi:10.1002/acr.22456.; Насонов ЕЛ, Каратеев ДЕ, Сатыбалдыев АМ и др. Ревматоидный артрит в Российской Федерации по данным Российского регистра больных артритом (сообщение I). Научно-практическая ревматология. 2016;54:50-62.; Nasonov E, Fatenejad S, Feist E, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with metho trexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Apr;81(4):469-479. doi:10.1136/annrheumdis-2021-219876. Epub 2021 Aug 3.; Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25;387(8):715-726. doi:10.1056/NEJMoa2201302.; Feist E, Fatenejad S, Grishin S, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Dec;81(12): 1661-1668. doi:10.1136/ard-2022-222630. Epub 2022 Sep 15.; Feist E, Fleischmann RM, Fatenejad S, et al. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Ann Rheum Dis. 2024 Oct 21;83(11):1454-1464. doi:10.1136/ard-2023-225473.; Ho Lee Y, Gyu Song G. Comparison of the efficacy and safety of tocilizumab, sari lumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials. Z Rheumatol. 2024 Feb;83(Suppl 1):97-106. doi:10.1007/s00393-022-01315-0. Epub 2023 Jan 6.; https://acrabstracts.org/abstract/the-impact-of-comorbidities-on-the-efficacy-of-il-6-inhibitor-olokizumab-compared-to-adalimumab/; Favalli EG. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol Ther. 2020 Sep;7(3):473-516. doi:10.1007/s40744-020-00219-2. Epub 2020 Jul 30.; Zeb S, Khan Z, Ashraf, et al. Relationship Between Serum Interleukin-6 Levels, Systemic Immune-Inflammation Index, and Other Biomarkers Across Different Rheumatoid Arthritis Severity Levels. Cureus. 2024 Oct 24;16(10):e72334. doi:10.7759/cureus.72334. eCollection 2024 Oct.; Berardicurti O, Ruscitti P, Pavlych V, et al. Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy. Expert Rev Clin Pharmacol. 2020 Jun;13(6): 593-604. doi:10.1080/17512433.2020.1772055. Epub 2020 Jun 8.; Lauper K, Mongin D, Bergstra SA, et al. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies. Joint Bone Spine. 2024 Mar;91(2):105671. doi:10.1016/j.jbspin.2023.105671. Epub 2023 Nov 30.; Wallace BI, England BR, Baker JF, et al. Lowering Expectations: Glucocorticoid Tapering Among Veterans With Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy. ACR Open Rheumatol. 2023 Sep;5(9):437-442. doi:10.1002/acr2.11584. Epub 2023 Jul 25.; Karateev АЕ, Polishchuk ЕY, Filatova ЕS, et al. Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study. Int J Rheum Dis. 2024 Oct;27(10):e15320. doi:10.1111/1756-185X.15320.; Потапова АС, Каратеев АЕ, Поли щук ЕЮ и др. Снижение потребности в глюкокортикоидах на фоне терапии генно-инженерными биологическими препаратами и ингибиторами янус-киназ при ревматоидном артрите: данные реальной клинической практики. Терапевтический архив. 2024;96(5):465-470.; Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency. J Clin Endocrinol Metab. 2024 Jun 17;109(7):1657-1683. doi:10.1210/clinem/dgae250.

Verfügbarkeit: https://mrj.ima-press.net/mrj/article/view/1738
https://doi.org/10.14412/1996-7012-2025-2-39-49

Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real clinical practice in Kazakhstan ; Эффективность и безопасность олокизумаба в лечении ревматоидного артрита в реальной клинической практике в Казахстане

Autoren: G. A. Togizbayev D. I. Parpiyeva D. A. Maksot et al.

Quelle: Modern Rheumatology Journal; Принято в печать ; Современная ревматология; Принято в печать ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-0-0

Schlagwörter: безопасность, олокизумаб, ингибиторы ИЛ-6, эффективность

Dateibeschreibung: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1732/1576; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038.; Chen, Y.-C.; Huang, C.-M.; Liu, T.-Y.; Wu, N.; Chan, C.-J.; Shih, P.-Y.; Chen, H.-H.; Chen, S.-Y.; Tsai, F.-J. Effects of Human Leukocyte Antigen DRB1 Genetic Polymorphism on Anti-Cyclic Citrullinated Peptide (ANTI-CCP) and Rheumatoid Factor (RF) Expression in Rheumatoid Arthritis (RA) Patients. Int. J. Mol. Sci. 2023, 24, 12036. https://doi.org/10.3390/ijms241512036.; Prasad P, Kumar A, Gupta R, Juyal RC, Thelma BK. Caucasian and Asian specific rheumatoid arthritis risk loci reveal limited replication and apparent allelic heterogeneity in north Indians. PLoS One. 2012;7(2):e31584. doi:10.1371/journal.pone.0031584. Epub 2012 Feb 15. PMID: 22355377; PMCID: PMC3280307.; Felson DT. Comparing the prevalence of rheumatic diseases in China with the rest of the world. Arthritis Res Ther. 2008;10(1):106. doi:10.1186/ar2369. Epub 2008 Feb 25. PMID: 18341701; PMCID: PMC2374465.; Suenaga, Y., Yasuda, M., Zhao, Y. et al. Rheumatoid arthritis in the Northeastern area of the People's Republic of China and Western Japan. Clin Rheumatol 14, 76–80 (1995). https://doi.org/10.1007/BF02208088; Baek HJ, Lim MJ, Park W, Park SH, Shim SC, Yoo DH, Kim HA, Lee SK, Lee YJ, Park YE, Cha HS, Song YW. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis. Korean J Intern Med. 2019 Jul;34(4):917-931. doi:10.3904/kjim.2017.159. Epub 2018 Jan 17. PMID: 29334721; PMCID: PMC6610180.; Jinno, S., Onishi, A., Dubreuil, M. et al. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study. Arthritis Res Ther 23, 116 (2021). https://doi.org/10.1186/s13075-021-02496-w; Каратеев Д.Е., Лучихина Е.Л. Ингибиторы интерлейкина 6 в терапии ревматоидного артрита. Эффективная фармакотерапия. 2022; 18 (8): 16–21. DOI 10.33978/2307-3586-2022-18-8-16-21. Эффективная фармакотерапия. 2022.Том 18. № 8. Ревматология, травматология и ортопедия DOI 10.33978/2307-3586-2022-18-8-16-21.; Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, Samsonov MY, Fleischmann RM; CREDO2 Group. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25;387(8):715-726. doi:10.1056/NEJMoa2201302. PMID: 36001712.; Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S93-S99.; Baimukhamedov C, Togizbayev G, Mirakhmedova K, Mamasaidov A, Shukurova S. Increasing autoimmune rheumatic diseases as a consequence of the COVID-19 pandemic: A hypothesis or fact? Int J Rheum Dis. 2024 Jan;27(1):e15011. doi:10.1111/1756-185X.15011. Epub 2023 Dec 22; Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Kanzo Amano,Ryuji Nagamine, Won Park, Kazuko Shiozawa, Michishi Tsukano, James Cheng-Chung Wei, Jing Shao, Osamu Togo & Hideki Mashimo (2016) Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial, Modern Rheumatology, 26:1, 15-23, DOI:10.3109/14397595.2015.1074648.

Verfügbarkeit: https://mrj.ima-press.net/mrj/article/view/1732

Experience of using the interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis in real-life clinical practice (based on data from Tyumen Regional Rheumatology Center) ; Опыт применения ингибитора интерлейкина 6 олокизумаба у пациентов с ревматоидным артритом в реальной клинической практике (по материалам Тюменского областного ревматологического центра)

Autoren: I. M. Patrikeeva Yu. A. Lushpaeva N. V. Knaub et al.

Quelle: Modern Rheumatology Journal; Том 19, № 1 (2025); 57-63 ; Современная ревматология; Том 19, № 1 (2025); 57-63 ; 2310-158X ; 1996-7012

Schlagwörter: гуманизированное моноклональное антитело, olokizumab, interleukin-6 inhibitor, humanized monoclonal antibody, олокизумаб, ингибитор интерлейкина 6

Dateibeschreibung: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1703/1559; Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57. doi:10.1038/ni.3153.; Kondo N, Kuroda T, Kobayashi D. Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis. Int J Mol Sci. 2021 Oct 10;22(20):10922. doi:10.3390/ijms222010922.; Pandolfi F, Franza L, Carusi V, et al. Interleukin-6 in Rheumatoid Arthritis. Int J Mol Sci. 2020 Jul 23;21(15):5238. doi:10.3390/ijms21155238.; Kishimoto T, Kang S. IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. Annu Rev Immunol. 2022 Apr 26;40:323-348. doi:10.1146/annurev-immunol-101220-023458. Epub 2022 Feb 3.; Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford). 2018 Feb 1;57(suppl_2):ii43-ii50. doi:10.1093/rheumatology/kex513.; Taylor PC, Fautrel B, Piette Y, et al. Treat-to-target in rheumatoid arthritis: a realworld study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD Open. 2022 Dec;8(2):e002658. doi:10.1136/rmdopen-2022-002658.; Kim GW, Lee NR, Pi RH, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res. 2015;38(5):575-84. doi:10.1007/s12272-015-0569-8. Epub 2015 Feb 4.; Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017 Nov;77(17): 1865-1879. doi:10.1007/s40265-017-0829-7.; Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review. Mod Rheumatol. 2019 Mar;29(2):258-267. doi:10.1080/14397595.2018.1546357. Epub 2019 Jan 3.; Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? BioDrugs. 2024 Jan;38(1):61-71. doi:10.1007/s40259-023-00634-1. Epub 2023 Nov 21.; Nasonov E, Fatenejad S, Feist E, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Apr; 81(4):469-479. doi:10.1136/annrheumdis2021-219876. Epub 2021 Aug 3.; Smolen JS, Feist E, Fatenejad S, et al; CREDO2 Group. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25;387(8):715-726. doi:10.1056/NEJMoa2201302.; Feist E, Fleischmann RM, Fatenejad S и др. Комбинация олокизумаба с метотрексатом: безопасность и эффективность за 106 недель терапии. Современная ревматология. 2024;18(6):21-35. doi:10.14412/1996-7012-2024-6-21-35; Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-8. doi:10.1136/ard.2010.138461.; Smolen, Josef S, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi:10.1136/ard-2022-223356. Epub 2022 Nov 10.; Van der Heijde D. Structural damage in rheumatoid arthritis as visualized through radiographs. Arthritis Res. 2002;4 Suppl 2 (Suppl 2):S29-33. doi:10.1186/ar550. Epub 2002 Mar 27.; Каратеев ДЕ, Степанова ЕА, Лучихина ЕЛ. Методические рекомендации по рентгенологическим методам исследования при ревматоидном артрите и анкилозирующем спондилите. Эффективная фармакотерапия. 2022;18(18):12-25.; Федеральные клинические рекомендации по диагностике и лечению ревматоидного артрита. 2021. https://cr.minzdrav.gov.ru/recomend/250_2; Gabay C, Emery P, van Vollenhoven R, et al; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, doubleblind, controlled phase 4 trial. Lancet. 2013 May 4;381(9877):1541-50. doi:10.1016/S0140-6736(13)60250-0. Epub 2013 Mar; Su QY, Luo J, Zhang Y, et al. Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis. J Transl Med. 2024 Aug 28;22(1):795. doi:10.1186/s12967-024-05569-x.; Моисеев СВ, Новиков ПИ, Чеботарева НВ и др. Олокизумаб в лечении ревматоидного артрита. Клиническая фармакология и терапия. 2021;30(2):67-74.; Kretsos K, Golor G, Jullion A, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi:10.1002/cpdd.121. Epub 2014 May 26.; Yip RML, Yim CW. Role of Interleukin 6 Inhibitors in the Management of Rheumatoid Arthritis. J Clin Rheumatol. 2021 Dec 1;27(8): e516-e524. doi:10.1097/RHU.0000000 000001293.; Genovese MC, van der Heijde D, Lin Y, et al. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 2019 Aug 1;5(2): e000887. doi:10.1136/rmdopen-2018-000887.

Verfügbarkeit: https://mrj.ima-press.net/mrj/article/view/1703
https://doi.org/10.14412/1996-7012-2025-1-57-63

REVMATOİD ARTRİTİN MÜALİCƏSİNDƏ İL-6 ƏLEYHİNƏ MONOKLONAL ANTİCİSİMLƏRİN TƏTBİQİNİN PERSPEKTİVLƏRİ: PROSPECTS FOR THE CLINICAL APPLICATION OF MONOCLONAL ANTIBODIES TO IL-6 IN RHEUMATOID ARTHRITIS

Quelle: Azerbaijan Medical Journal. :148-154

Schlagwörter: rheumatoid arthritis, interleykin-6, interleukin-6, интерлейкин-6, olokizumab, ревматоидный артрит, моноклональные антитела, monoclonal antibodies, revmatoid artrit, monoklonal anticisimciklər, олокизумаб, 3. Good health

Olokizumab in patients with inflammatory phenotype of osteoarthritis, treatment experience ; Опыт применения олокизумаба у пациентов с воспалительным фенотипом остеоартрита

Autoren: A. M. Lila L. I. Alekseeva E. A. Taskina et al.

Weitere Verfasser: A. M. Lila L. I. Alekseeva E. A. Taskina et al.

Quelle: Modern Rheumatology Journal; Том 18, № 3 (2024); 14-24 ; Современная ревматология; Том 18, № 3 (2024); 14-24 ; 2310-158X ; 1996-7012

Schlagwörter: олокизумаб, inflammatory phenotype, interleukin 6, olokizumab, воспалительный фенотип, интерлейкин 6

Dateibeschreibung: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1584/1467; https://mrj.ima-press.net/mrj/article/view/1584/1490; GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023 Aug 21;5(9):e508-e522. doi:10.1016/S2665-9913(23)00163-7.; Muthu S. Osteoarthritis, an old wine in a new bottle! World J Orthop. 2023 Jan 18;14(1): 1-5. doi:10.5312/wjo.v14.i1.1.; Мазуров ВИ, Лила АМ, Алексеева ЛИ и др. Мультиморбидность при остеоартрите и плейотропные эффекты симптоматических средств замедленного действия. Резолюция международного мультидисциплинарного совета экспертов. Современная ревматология. 2023;17(5):123-131. doi:10.14412/1996-7012-2023-5-123-131.; Sanchez-Lopez E, Coras R, Torres A, et al. Synovial inflammation in osteoarthritis progression. Nat Rev Rheumatol. 2022 May;18(5): 258-275. doi:10.1038/s41584-022-00749-9.; Herrero-Beaumont G, Roman-Blas JA, Bruyere O, et al. Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. Maturitas 2017 Feb:96:54-57. doi:10.1016/j.maturitas.2016.11.013.; Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017 Feb 2;19(1):18. doi:10.1186/s13075-017-1229-9.; Calvet J, Berenguer-Llergo A, Orellana C, et al. Specific-cytokine associations with outcomes in knee osteoarthritis subgroups: breaking down disease heterogeneity with phenotyping. Arthritis Res Ther. 2024 Jan 11;26(1):19. doi:10.1186/s13075-023-03244-y.; Dell'Isola A, Allan R, Smith SL, et al. Identification of clinical phenotypes in knee osteoarthritis : a systematic review of the literature. BMC Musculoskelet Disord. 2016 Oct 12;17(1):425. doi:10.1186/s12891-016-1286-2.; Henrotin Y. Osteoarthritis in year 2021: biochemical markers. Osteoarthritis Cartilage. 2022 Feb;30(2):237-248. doi:10.1016/j.joca.2021.11.001. Epub 2021 Nov 16.; Angelini F, Widera P, Mobasheri A, et al. Osteoarthritis endotype discovery via clustering of biochemical marker data. Ann Rheum Dis. 2022 May;81(5):666-675. doi:10.1136/annrheumdis-2021-221763.; Li S, Cao P, Chen T, Ding C. Latest insights in disease-modifying osteoarthritis drugs development. Ther Adv Musculoskelet Dis. 2023 May 13:15:1759720X231169839. doi:10.1177/1759720X231169839.; Vrouwe JPM, Burggraaf J, Kloppenburg M, Stuurman FE. Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments. Osteoarthr Cartil Open. 2021 Sep 8;3(4):100212. doi:10.1016/j.ocarto.2021.100212.; Лапкина НА, Баранов АА, Левшин НЮ и др. Динамика клинических проявлений и концентрации цитокинов у больных ревматоидным артритом на фоне терапии олокизумабом. Научно-практическая ревматология. 2023;61(4):475-484.; Akeson G, Malemud CJ. A Role for Soluble IL-6 Receptor in Osteoarthritis. J Funct Morphol Kinesiol. 2017;2(3):27. doi:10.3390/jfmk2030027. Epub 2017 Aug 2.; Beekhuizen M, Gierman LM, van Spil WE, et al. An explorative study comparing levels of soluble mediators in control and osteoarthritic synovial fluid. Osteoarthritis Cartilage. 2013 Jul;21(7):918-22. doi:10.1016/j.joca.2013.04.002. Epub 2013 Apr 15.; Sohn DH, Sokolove J, Sharpe O, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via toll-like receptor 4. Arthritis Res Ther. 2012 Jan 8;14(1):R7. doi:10.1186/ar3555.; Wang ZW, Chen L, Hao XR, et al. Elevated levels of interleukin-1beta, interleukin-6, tumor necrosis factoralpha and vascular endothelial growth factor in patients with knee articular cartilage injury. World J Clin Cases. 2019 Jun 6;7(11):1262-1269. doi:10.12998/wjcc.v7.i11.1262.; Livshits G, Zhai G, Hart DJ et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: the Chingford Study. Arthritis Rheum 2009;60 (7):2037–45. doi:10.1002/art.24598.; Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-alpha are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage. 2010 Nov;18(11):1441-7. doi:10.1016/j.joca.2010.08.016. Epub 2010 Sep 16.; Goekoop RJ, Kloppenburg M, Kroon HM, et al. Low innate production of interleukin-1beta and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthritis Cartilage. 2010 Jul;18(7):942-7. doi:10.1016/j.joca.2010.03.016. Epub 2010 Apr 22.; Tsuchida AI, Beekhuizen M, Rutgers M, et al. Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model. Arthritis Res Ther. 2012 Dec 3;14(6):R262. doi:10.1186/ar4107.; Tsuchida AI, Beekhuizen M, `t Hart MC, et al. Cytokine profiles in the joint depend on pathology, but are different between synovial fluid, cartilage tissue and cultured chondrocytes. Arthritis Res Ther. 2014 Sep 26;16(5):441. doi:10.1186/s13075-014-0441-0.; Guerne PA, Zuraw BL, Vaughan JH, et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest. 1989 Feb;83(2): 585-92. doi:10.1172/JCI113921.; Bondeson J, Wainwright SD, Lauder S, et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther. 2006;8(6): R187. doi:10.1186/ar2099.; Nguyen HN, Noss EH, Mizoguchi F, et al. Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators. Immunity. 2017 Feb 21; 46(2):220-232. doi:10.1016/j.immuni.2017.01.004.; Wiegertjes R, van de Loo FAJ, Blaney Davidson EN. A roadmap to target interleukin-6 in osteoarthritis. Rheumatology (Oxford). 2020 Oct 1;59(10):2681-2694. doi:10.1093/rheumatology/keaa248.; Distel E, Cadoudal T, Durant S, et al. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum. 2009 Nov; 60(11):3374-7. doi:10.1002/art.24881.; Pearson MJ, Herndler-Brandstetter D, Tariq MA, et al. IL-6 secretion in osteoarthritis patients is mediated by chondrocyte-synovial fibroblast cross-talk and is enhanced by obesity. Sci Rep. 2017 Jun 14;7(1):3451. doi:10.1038/s41598-017-03759-w.; Richette P, Latourte A, Sellam J, et al. Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann Rheum Dis. 2021 Mar;80(3):349-355. doi:10.1136/annrheumdis-2020-218547.; Sanchez Huerta JM, Galvez-Romero J, Lopez-Rodriguez W, Lopez A. UTILITY OF Tocilizumab in clinical manifestations of erosive osteoarthrosis of hands regional hospital issste puebla, Mεxico. Ann Rheum Dis. 2017; 76(Suppl 2):974. doi:10.1136/annrheumdis-2017-eular.6483.; Kretsos K, Golor G, Jullion A, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi:10.1002/cpdd.121. Epub 2014 May 26.

Verfügbarkeit: https://mrj.ima-press.net/mrj/article/view/1584
https://doi.org/10.14412/1996-7012-2024-3-14-24

Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic ; Результаты 12-недельного открытого неинтервенционного исследования эффективности и безопасности терапии препаратом олокизумаб у пациентов с ревматоидным артритом после переключения с анти-B-клеточной терапии в условиях пандемии SARS-CoV-2

Autoren: A. A. Akimova N. E. Banshchikova A. E. Sizikov et al.

Weitere Verfasser: A. A. Akimova N. E. Banshchikova A. E. Sizikov et al.

Quelle: Rheumatology Science and Practice; Vol 61, No 1 (2023); 25–33 ; Научно-практическая ревматология; Vol 61, No 1 (2023); 25–33 ; 1995-4492 ; 1995-4484

Schlagwörter: ритуксимаб, COVID-19, olokizumab, rituximab, олокизумаб

Dateibeschreibung: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3274/2255; Белов БС, Лила АМ. COVID-19 и ревматология: год спустя. Научно-практическая ревматология. 2021;59(1):31-36. doi:10.47360/1995-4484-2021-31-36; Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4; Liu M, Gao Y, Zhang Y, Shi S, Chen Y, Tian J. The association between severe or dead COVID-19 and autoimmune diseases: A systematic review and meta-analysis. J Infect. 2020;81(3):e93-e95. doi:10.1016/j.jinf.2020.05.065; D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020;79(9):1156-1162. doi:10.1136/annrheumdis-2020-217888; Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi:10.1136/annrheumdis-2020-217871; Galarza-Delgado D.Á. et al. Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy // Clin Rheumatol. 2021. Vol. 40, № 3. P. 1197-1199; Loarce-Martos J, García-Fernández A, López-Gutiérrez F, García-García V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: A descriptive study. Rheumatol Int. 2020;40(12):2015-2021. doi:10.1007/s00296-020-04699-x; Королев МА, Летягина ЕА, Сизиков АЭ, Богодерова ЛА, Убшаева ЮБ, Омельченко ВО, и др. Иммунов оспалительные ревматические заболевания и COVID-19: анализ клинических исходов по данным регистра пациентов Новосибирской области, получающих терапию генно-инженерными биологическими препаратами. Терапевтический архив. 2022;94(5):636-641. doi:10.26442/00403660.2022.05.201502; Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al.; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors; FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. Lancet Rheumatol. 2021;3(6):e419-e426. doi:10.1016/S2665-9913(21)00059-X; Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-254. doi:10.47360/1995-4484-2021-239-254; Авдеев СН, Адамян ЛВ, Алексеева УИ, Багненко СФ, Баранов АА, Баранова НН, и др. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). 2022.; Dernoncourt A, Schmidt J, Duhaut P, Liabeuf S, Gras-Champel V, Masmoudi K, et al. COVID-19 in DMARDtreated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. Fundam Clin Pharmacol. 2022;36(1):199-209. doi:10.1111/fcp.12695; Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465-470. doi:10.1038/s41584-020-0451-z; Jiang Y, Zhao T, Zhou X, Xiang Y, Gutierrez-Castrellon P, Ma X. Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. MedComm. 2022;3(3):e154. doi:10.1002/mco2.154; World Health Organization. Clinical management of COVID-19: Living guideline. 2022 Sep 15. URL: http://apps.who.int/iris. 2022 (Accessed: DD Month 2022).; National Institutes of Health. COVID-19 treatment guidelines panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. URL: https://www.covid19treatmentguidelines.nih.gov. (Accessed: DD Month 2022).; Насонов ЕЛ, Файст Е. Перспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6). Научно-практическая ревматология. 2022;60(5):505-518. doi:10.47360/1995-4484-2022-505-518; Насонов ЕЛ, Авдеева АС. Деплеция В-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (COVID-19). Научно-практическая ревматология. 2021;59(4):384-393. doi:10.47360/1995-4484-2021-384-393; Личиницер МР, Степанова ЕВ. Новые противоопухолевые препараты на основе моноклональных антител. Российский медицинский журнал. 2002;14:609.; Баранов АА, Алексеева ЕИ, Бзарова ТМ, Валиева СИ, Денисова РВ, Исаева КБ, и др. Протокол ведения пациентов с ювенильным артритом. Вопросы современной педиатрии. 2013;12(1):37-56. doi:10.15690/vsp.v12i1.557; Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137-1146. doi:10.1136/annrheumdis-2021-220418; Антонов ВН, Игнатова ГЛ, Прибыткова ОВ, Слепцова СС, Стребкова ЕА, Худякова ЕА, и др. Опыт применения олокизу маба у больных COVID-19. Терапевтический архив. 2020;92(12):148-154. doi:10.26442/00403660.2020.12.200522; Бобкова СС, Жуков АА, Проценко ДН, Самойленко ВВ, Тюрин ИН Сравнительная эффективность и безопасность применения препаратов моноклональных антител к ИЛ-6 у пациентов с новой коронавирусной инфекцией COVID-19 тяжелого течения. Ретроспективное когортное исследование. Вестник интенсивной терапии имени А.И. Салтанова. 2021;(1):69-76. doi:10.21320/1818-474X-2021-1-69-76; Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40(7):1074-1081. doi:10.3899/jrheum.121389; Berger CT, Rebholz-Chaves B, Recher M, Manigold T, Daikeler T. Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses. Ann Rheum Dis. 2019;78(7):1012-1014. doi:10.1136/annrheumdis-2018-214704; Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7): 814-818. doi:10.1002/jmv.25801; Омельченко ВО, Летягина ЕА, Королев МА, Поспелова ТИ. Атеросклеротическое поражение брахиоцефальных артерий при ревматоидном артрите и его ассоциация с факторами сердечно-сосудистого риска. Сибирский журнал клинической и экспериментальной медицины. 2019;34(1):107-117. doi:10.29001/2073-8552-2019-34-1-107-117

Verfügbarkeit: https://rsp.mediar-press.net/rsp/article/view/3274
https://doi.org/10.47360/1995-4484-2023-25-33

Dynamics of clinical manifestations and cytokine concentrations in patients with rheumatoid arthritis on olokizumab therapy ; Динамика клинических проявлений и концентрации цитокинов у больных ревматоидным артритом на фоне терапии олокизумабом

Autoren: N. A. Lapkina A. A. Baranov N. Yu. Levshin et al.

Quelle: Rheumatology Science and Practice; Vol 61, No 4 (2023); 475-484 ; Научно-практическая ревматология; Vol 61, No 4 (2023); 475-484 ; 1995-4492 ; 1995-4484

Schlagwörter: олокизумаб, IL-6, olokizumab, интерлейкин 6

Dateibeschreibung: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3402/2307; Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi:10.1038/nrdp.2018.1; Favalli EG. Understanding the role of interleukin-6 (IL-6) in the joint and beyond: A comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther. 2020; 7(3):473-516. doi:10.1007/s40744-020-00219-2; Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335-345. doi:10.1038/s41584-020-0419-z; Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина-6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-599. [Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: Achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(6):590-599 (In Russ.)]. doi:10.14412/1995-4484-2017-590-599; Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина-6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-599. [Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: Achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(6):590-599 (In Russ.)]. doi:10.14412/1995-4484-2017-590-599ы; Scott LJ. Tocilizumab: A review in rheumatoid arthritis. Drugs. 2017;77(17):1865-1879. doi:10.1007/s40265-017-0829-7; Насонов ЕЛ, Лила АМ. Эффективность и безопасность сарилумаба (полностью человеческие моноклональные антитела к рецептору интерлейкина-6) при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2019;57(5):564-577. [Nasonov EL, Lila AM. The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: New evidence. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(5):564-577 (In Russ.)]. doi:10.14412/1995-4484-2019-564-57; Serio I, Tovoli F. Rheumatoid arthritis: New monoclonal antibodies. Drugs Today (Barc). 2018;54(3):219-230. doi:10.1358/dot.2018.54.3.2788019; Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007-1023. doi:10.1016/j.immuni.2019.03.026; Tanaka Y, Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: Studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis. 2014;73(9):1595-1597. doi:10.1136/annrheumdis-2013-205002; Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, et al. Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014;6(3):774-782. doi:10.4161/mabs.28612; Насонов ЕЛ, Файст Е. Перспективы ингибиции интерлейки-на-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6). Научно-практическая ревматология. 2022;60(5):505-518. [Nasonov EL, Feist E. The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(5):505-518 (In Russ.)]. doi:10.47360/1995-4484-2022-505-518; Моисеев СВ, Новиков ПИ, Чеботарева НВ, Гуляев СВ, Буланов НМ, Шевцова ТП, и др. Олокизумаб в лечении ревматоидного артрита. Клиническая фармакология и терапия. 2021;30(2): 67-74. [Moiseev SV, Novikov PI, Chebotareva NV, Gulyaev SV, Bulanov NM, Shevtsova TP, et al. Olokizumab for treatment of rheumatoid arthritis. Clinical Pharmacolology and Therapy. 2021; 30(2):67-74 (In Russ.)]. doi:10.32756/0869-5490-2021-2-67-74; Акимова АА, Банщикова НЕ, Сизиков АЭ, Муллагалиев АА, Летягина ЕА, Ильина НА, и др. Результаты 12-недельного открытого неинтервенционного исследования эффективности и безопасности терапии препаратом олокизумаб у пациентов с ревматоидным артритом после переключения с анти-B-клеточной терапии в условиях пандемии SARS-CoV-2. Научно-практическая ревматология. 2023;61(1):25-33. [Akimova AA, Banshchikova NE, Sizikov AE, Mullagaliev AA, Letyagina EA, Ilina NA, et al. Results of a 12-week open-label, noninterventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic (review). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(1): 25-33 (In Russ.)]. doi:10.47360/1995-4484-2023-25-33; Лисицына ТА, Абрамкин АА, Вельтищев ДЮ, Серавина ОФ, Ковалевская ОБ, Борисова АБ, и др. Эффективность олокизу маба в отношении коморбидного депрессивного расстройства у больных ревматоидным артритом: предварительные результаты исследования. Научно-практическая ревматология. 2023;61(2):188-198. [Lisitsyna TA, Abramkin AA, Veltishchev DYu, Seravina OF, Kovalevskaya OB, Borisova AB, et al. Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(2):188-198 (In Russ.)]. doi:10.47360/1995-4484-2023-188-198; Баранов АА, Виноградова ИБ, Аношенкова ОН, Антипова ОВ, Богданова ЕА, Грабовецкая ЮЮ, и др. Ведение больных ревматоидным артритом в реальной клинической практике: опыт переключения с терапии ингибитором рецепторов интерлейкина-6 на ингибитор интерлейкина-6 (олокизумаб). Научно-практическая ревматология. 2023;61(3):307-319. [Baranov AA, Vinogradova IB, Anoshenkova ON, Antipova OV, Bogdanova EA, Grabovetskaya YY, et al. Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab). Nauchno-Prakticheskaya Revmato logia = Rheumatology Science and Practice. 2023;61(3):307-319 (In Russ.)]. doi:10.47360/1995-4484-2023-307-319; Kretsos K, Jullion A, Zamacona M, Harari O, Shaw S, Boulanger B, et al. Model-based optimal design and execution of the first-inpatient trial of the anti-IL-6, olokizumab. CPT Pharmacometrics Syst Pharmacol. 2014;3(6):e119. doi:10.1038/psp.2014.17; Fleischmann R, Kivitz AJ, Wagner F, Feinstein JA, Fuhr U, Rech J, et al. A pilot study investigating the tolerability and pharmacodynamic effect of single intravenous/subcutaneous doses of olokizumab, an anti-interleukin-6 monoclonal antibody, in patients with rheumatoid arthritis. Arthr Rheumat. 2012;64(10 Suppl):576-577.; Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi:10.1002/art.27584; Насонов ЕЛ (ред.). Ревматоидный артрит. Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2020. [Nasonov EL (ed). Rheumatoid arthritis. Rheumatology. Russian clinical guidelines. Moscow:GEOTAR-Media;2020 (In Russ.)].; Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes IB, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: An update. Ann Rheum Dis. 2023;82(6):773-787. doi:10.1136/ard-2022-222784; Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova DG, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: Efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(4):469-479. doi:10.1136/annrheumdis-2021-219876; Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, et al.; CREDO2 Group. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2022;387(8):715-726. doi:10.1056/NEJMoa2201302; Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: Efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(12):1661-1668. doi:10.1136/ard-2022-222630; Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers:A randomized phase I study. Clin Pharmacol Drug Dev. 2014;3(5):388-395. doi:10.1002/cpdd.121; A multicenter, randomized, double-blind, placebo-controlled, single dose study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of intravenous and subcutaneous CDP6038 in male and female subjects with rheumatoid arthritis on a stable dose of methotrexate: Clinical Study Report RA0010 (final). UCB Celltech;2011.; Robak T, Gladalska A, Stepień H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 1998;7(5):347-353. doi:10.1080/09629359890875; Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-3964. doi:10.1182/blood-2008-05-155846; Мазуров ВИ, Зоткин ЕГ, Гайдукова ИЗ, Иливанова ЕП, Кропотина ТВ, Плаксина ТВ, и др. Эффективность и безопасность применения левилимаба в комбинации с метотрексатом у пациентов с ревматоидным артритом: результаты II фазы исследования AURORA. Научно-практическая ревматология. 2021;59(2):141-151. [Mazurov VI, Zotkin EG, Gaydukova IZ, Ilivanova EP, Kropotina TV, Plaksina TV, et al. Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):141-151 (In Russ.)]. doi:10.47360/1995-4484-2021-141-151; Hayakawa M, Izumi K, Higashida-Konishi M, Ushikubo M, Tsukamoto M, Akiya K, et al. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: A case-based review. Rheumatol Int. 2019;9(1):161-166. doi:10.1007/s00296-018-4175-1; Chen YT, Chang CH. Tocilizumab-induced psoriasis in a patient with rheumatoid arthritis: A case report and literature review. Dermatol Sin. 2021;39:89-90. doi:10.4103/ds.ds_57_20; Лапкина НА, Баранов АА, Абайтова НЕ, Левшин НЮ, Авдеева АС, Леонтьева ЕА, и др. Динамика клинических проявлений и концентрации цитокинов у больных ревматоидным артритом на фоне терапии тофацитинибом. Научно-практическая ревматология. 2021;59(6):693-699. [Lapkina NA, Baranov AA, Abaytova NE, Levshin NYu, Avdeyeva AS, Leontyeva EA, et al. Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(6):693-699 (In Russ.)]. doi:10.47360/1995-4484-2021-693-699; Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно-практическая ревматология. 2014;52(2):209-221. [Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: Tofacitinib. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(2):209-221 (In Russ.)]. doi:10.14412/1995-4484-2014-209-221

Verfügbarkeit: https://rsp.mediar-press.net/rsp/article/view/3402
https://doi.org/10.47360/1995-4484-2023-475-484

Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study ; Эффективность олокизумаба в отношении коморбидного депрессивного расстройства у больных ревматоидным артритом: предварительные результаты исследования

Autoren: T. A. Lisitsyna A. A. Abramkin D. Yu. Veltishchev et al.

Weitere Verfasser: T. A. Lisitsyna A. A. Abramkin D. Yu. Veltishchev et al.

Quelle: Rheumatology Science and Practice; Vol 61, No 2 (2023); 188-198 ; Научно-практическая ревматология; Vol 61, No 2 (2023); 188-198 ; 1995-4492 ; 1995-4484

Schlagwörter: олокизумаб, rheumatoid arthritis, depression, cognitive disorders, olokizumab, ревматоидный артрит, депрессия, когнитивные нарушения

Dateibeschreibung: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3321/2274; Liao KP, Karlson EW. Classification and epidemiology of rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). Rheumatology. Elsevier Mosby: Maryland Heights, MO, USA;2015:691-697.; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-2038. doi:10.1016/S0140-6736(16)30173-8; Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62-68. doi:10.1136/annrheumdis-2013-204223; Vitturi BK, Nascimento BAC, Alves BR, de Campos FSC, Torigoe DY. Cognitive impairment in patients with rheumatoid arthritis. J Clin Neurosci. 2019;69:81-87. doi:10.1016/j.jocn.2019.08.027; Абрамкин АА, Лисицина ТА, Вельтищев ДЮ, Серавина ОФ, Ковалевская ОБ, Глухова СИ, и др. Рекуррентная депрессия и выраженность суставной деструкции у больных ревматоидным артритом. Терапевтический архив. 2020;92(5):22-32. doi:10.26442/00403660.2020.05.000624; Ionescu CE, Popescu CC, Agache M, Dinache G, Codreanu C. Depression in rheumatoid arthritis: A narrative review – Diagnostic challenges, pathogenic mechanisms and effects. Medicina. 2022;58:1637. doi:10.3390/medicina58111637; Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696-1709. doi:10.1038/mp.2016.3; Khandaker GM, Dantzer R, Jones PB. Immunopsychiatry: Important facts. Psychol Med. 2017;47(13):2229-2237. doi:10.1017/S0033291717000745; Ting EY, Yang AC, Tsai SJ. Role of interleukin-6 in depressive disorder. Int J Mol Sci. 2020;21(6):2194. doi:10.3390/ijms21062194; Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин 6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318-327. doi:10.14412/1995-4484-2019-318-327; Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: Towards precision medicine. Nat Rev Drug Discov. 2022;21(3):224-244. doi:10.1038/s41573-021-00368-1; Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova DG, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: Efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(4):469-479. doi:10.1136/annrheumdis-2021-219876; Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: Efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(12):1661-1668. doi:10.1136/ard-2022-222630; Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, et al.; CREDO2 Group. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2022;387(8):715-726. doi:10.1056/NEJMoa2201302; Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S14-S36. doi:10.1002/acr.20621; Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. doi:10.1192/bjp.134.4.382; Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55. doi:10.1111/j.2044-8341.1959.tb00467.x; Драгунская ЛС. Изучение признаков депрессивных состояний методом «Пиктограммы». Экспериментальные исследования в патопсихологии. М.;1976.; Логинова СВ, Рубинштейн СЯ. О применении метода «пиктограмм» для экспериментального исследования мышления психических больных. М.;1972.; Зейгарник БВ. Нарушения мышления у психически больных: экспериментально-психологическое исследование. М.;1958.; Зейгарник БВ. Патология мышления. М.:Издательство МГУ;1962.; Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: Dimensions and practical applications. Health Qual Life Outcomes. 2003;9:20.; Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727-1736. doi:10.1007/s11136-011-9903-x; Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S263-S286. doi:10.1002/acr.20579; Levis B, Sun Y, He C, Wu Y, Krishnan A, Bhandari PM, et al. Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression: Systematic review and meta-analysis. JAMA. 2020;323(22):2290-2300. doi:10.1001/jama.2020.6504; Wittenberg GM, Stylianou A, Zhang Y, Sun Y, Gupta A, Jagannatha PS, et al. Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Mol Psychiatry. 2020;25(6):1275-1285. doi:10.1038/s41380-019-0471-8; Behrens F, Burmester GR, Feuchtenberger M, Kellner H, Kuehne C, Liebhaber A, et al. Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care. Clin Exp Rheumatol. 2022;40(3):551-559. doi:10.55563/clinexprheumatol/yu55rd; Tiosano S, Yavne Y, Watad A, Langevitz P, Lidar M, Feld J, et al. The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis. Eur J Clin Invest. 2020;50(9):e13268. doi:10.1111/eci.13268; Salvadore G, Nash A, Bleys C. A double-blind, placebo-controlled, multicenter study of sirukumab as adjunctive treatment to a monoaminergic antidepressant in adults with major depressive disorder. Neuropsychopharmacology. 2018;43:S292.; Girgis RR, Ciarleglio A, Choo T, Haynes G, Bathon JM, Cremers S, et al. A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology. 2018;43(6):1317-1323. doi:10.1038/npp.2017.258; Bazzichi L, Nacci F, Sinigaglia L, Bianchino L, Caporali R. Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: Subanalysis of Italian data from a multicenter phase IIIb/IV trial. Clin Rheumatol. 2019;38(3):841-849. doi:10.1007/s10067-018-4327-4; Strand V, Joseph G, van Hoogstraten H, Chen CI, Fan C, Carita P, et al. Impact of sarilumab on health related quality of life (HRQoL), fatigue, and sleep in rheumatoid arthritis patients at week 24-results of a phase 3, randomized, double-blind, placebo-controlled, multi-center study. Arthritis Rheumatol. 2014;66:1522.

Verfügbarkeit: https://rsp.mediar-press.net/rsp/article/view/3321
https://doi.org/10.47360/1995-4484-2023-188-198

Experience with the interleukin 6 inhibitor (Olokizumab) in patients with rheumatoid arthritis in real clinical practice: Influence on inflammatory activity and disease outcomes ; Опыт применения ингибитора интерлейкина 6 (олокизумаба) у больных ревматоидным артритом в реальной клинической практике: влияние на воспалительную активность и исходы заболевания

Autoren: N. A. Lapkina A. A. Baranov N. E. Abaytova et al.

Quelle: Rheumatology Science and Practice; Vol 61, No 5 (2023); 554-561 ; Научно-практическая ревматология; Vol 61, No 5 (2023); 554-561 ; 1995-4492 ; 1995-4484

Schlagwörter: оцениваемые пациентом, IL-6 inhibitors, olokizumab, disease activity, patient’s reported outcomes, ингибитор ИЛ-6, олокизумаб, активность заболевания, исходы

Dateibeschreibung: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3437/2316; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. doi:10.1016/S0140-6736(16)30173-8; Favalli EG. Understanding the role of interleukin-6 (IL-6) in the joint and beyond: A comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther. 2020;7(3):473-516. doi:10.1007/s40744-020-00219-2; Choy EH, De Benedetti F, Takeuchi T, Hashizume М, John MR, Kishimoto Т. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16:335-345. doi:10.1038/s41584-020-0419-z; Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина-6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-599. doi:10.14412/1995-4484-2017-590-599; Obreja O, Biasio W, Andratsch M, Lips KS, Rathee PK, Ludwig A, et al. Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons. Brain. 2005;128(Pt 7): 1634-1641. doi:10.1093/brain/awh490; Chrousos GP. The hypothalamic-pituitaryadrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332: 1351-1362. doi:10.1056/NEJM199505183322008; Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993;77(6):1690-1694. doi:10.1210/jcem.77.6.8263159; Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: Evidence from randomized controlled trials. Am J Manag Care. 2008;14(4):234.; Van Tuyl LH, Michaud K. Patient-reported outcomes in rheumatoid arthritis. Rheum Dis Clin North Am. 2016;42(2):219-237. doi:10.1016/j.rdc.2016.01.010:2250-2256; Насонов ЕЛ, Файст Е. Перспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6). Научно-практическая ревматология. 2022;60(5):505-518. doi:10.47360/1995-4484-2022-505-518; Nasonov E, Fatenejad S, Korneva E, Krechikova D, Maslyansky A, Plaksina T, et al. Safety and efficacy of olokizumab in a phase III trial of patients with moderately to severely active rheumatoid arthritis inadequately controlled by methotrexate – CREDO1 study. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/safety-and-efficacy-of-olokizumab-in-a-phase-iii-trial-ofpatients-with-moderately-to-severely-active-rheumatoid-arthritisinadequately-controlled-by-methotrexate-credo1-study (Accessed: 7th July 2020).; Nasonov E, Stoilov R, Tyabut T on behalf of Saeed Fatenejad (United States of America), Krechikova D, Korneva E, Maslyansky A, et al. OP0021 Olokizumab, monoclonal antibody against IL6, in patients with moderately to severely active rheumatoid arthritis inadequately controlled by methotrexate: Efficacy and safety results of phase III CREDO-1 study. Ann Rheum Dis. 2020;79:16-17. doi:10.1136/annrheumdis-2020-eular.1688; Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, et al; CREDO2 Group. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2022;387(8): 715-726. doi:10.1056/NEJMoa2201302; Kretsos K, Jullion A, Zamacona M, Harari O, Shaw S, Boulanger B, et al. Model-based optimal design and execution of the first-inpatient trial of the anti-IL-6, olokizumab. CPT Pharmacometrics Syst Pharmacol. 2014;3(6):e119. doi:10.1038/psp.2014.17; Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014;3(5):388-395. doi:10.1002/cpdd.121; Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: Outcomes of a randomised phase IIb study. Ann Rheum Dis. 2014;73(9):1607-1615. doi:10.1136/annrheumdis-2013-204760; Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol. 2016;26(1):15-23. doi:10.3109/14397595.2015.1074648; Моисеев СВ, Новиков ПИ, Чеботарева НВ, Гуляев СВ, Буланов НМ, Шевцова ТП, и др. Олокизумаб в лечении ревматоидного артрита. Клиническая фармакология и терапия. 2021;30(2): 67-74. doi:10.32756/0869-5490-2021-2-67-74; Насонов ЕЛ, Лисицына ТА, Зонова ЕВ, Кузькина СМ. Влияние олокизумаба на исходы, оцениваемые пациентом с ревматоидным артритом: результаты двойного слепого рандомизированного плацебо-контролируемого многоцентрового исследования III фазы (CREDO 1). Научно-практическая ревматология. 2021;59(1):62-69. doi:10.47360/1995-4484-2021-62-69; Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi:10.1002/art.27584; Насонов ЕЛ, Каратеев ДЕ (ред.). Ревматоидный артрит. Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2020.; Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729-740. doi:10.1002/art.1780360601; Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: Status and review. Arthritis Care Res. 1992;5(3):119-129. doi:10.1002/art.1790050303; Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):811-819.; Ware JE, Kosinski M, Keller SK: SF-36 physical and mental health summary scales: A user’s manual. Boston:New England Medical Center, The Health Institute;1994.; Вассерман ЛИ, Вукс АЯ, Иовлев БВ, Карпова ЭБ. Психологическая диагностика отношения к болезни. Пособие для врачей. СПб.;2005.; Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716; Ересько ДБ, Исурина ГЛ, Кайдановская ЕВ, Карвасарский БД, Карпова ЭБ, Корепанова ТГ, и др. Алекситимия и методы её определения при пограничных психосоматических расстройствах. Пособие для врачей и медицинских психологов. СПб.;2005.; Vallieres L, Rivest S. Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia. Endocrinology. 1999;140(9):3890-3903. doi:10.1210/endo.140.9.6983; Du X, Pang TY. Is dysregulation of the HPA-axis a core pathophysiology mediating comorbid depression in neurodegenerative diseases? Front Psychiatry. 2015;6:32. doi:10.3389/fpsyt.2015.00032; Girotti M, Donegan JJ, Morilak DA. Influence of hypothalamic IL-6/gp130 receptor signaling on the HPA axis response to chronic stress. Psychoneuroendocrinology. 2013;38(7):1158-1169. doi:10.1016/j.psyneuen. 2012.11.004; Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457. doi:10.1016/j.biopsych.2009.09.033; Kern S, Skoog I, Börjesson-Hanson A, Blennow K, Zetterberg H, Ostling S, et al. Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a populationbased sample. Brain Behav Immun. 2014;41:55-58. doi:10.1016/j.bbi.2014.05.006; Zhou AJ, Lee Y, Salvadore G, Hsu B, Fonseka TM, Kennedy SH, et al. Sirukumab: A potential treatment for mood disorders? Adv Ther. 2017;34(1):78-90. doi:10.1007/s12325-016-0455-x; Лисицына ТА, Абрамкин АА, Вельтищев ДЮ, Серавина ОФ, Ковалевская ОБ, Борисова АБ и др. Эффективность олокизумаба в отношении коморбидного депрессивного расстройства у больных ревматоидным артритом: предварительные результаты исследования. Научно-практическая ревматология. 2023;61(2):188-198. doi:10.47360/1995-4484-2023-188-198

Verfügbarkeit: https://rsp.mediar-press.net/rsp/article/view/3437
https://doi.org/10.47360/1995-4484-2023-554-561

Clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis ; Клинический случай применения олокизумаба у пациента с диффузной формой системной склеродермии

Autoren: E. S. Kuvardin D. Yu. Andreev P. A. Yastrebov et al.

Quelle: Rheumatology Science and Practice; Vol 60, No 5 (2022); 603-608 ; Научно-практическая ревматология; Vol 60, No 5 (2022); 603-608 ; 1995-4492 ; 1995-4484

Schlagwörter: интерлейкин-6, olokizumab, interleukin - 6, олокизумаб

Dateibeschreibung: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3230/2234; van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755. doi:10.1136/annrheumdis-2013-204424; Park EH, Strand V, Oh YJ, Song YW, Lee EB. Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study. Arthritis Res Ther. 2019;21(1):61. Published 2019 Feb 15. doi:10.1186/s13075-019-1842-x; van Leeuwen NM, Ciaffi J, Liem SIE, et al. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology (Oxford). 2021;60(8):3646– 3655. doi:10.1093/rheumatology/keaa827; Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017; 390(10103):1685–1699. doi:10.1016/S0140-6736(17)30933-9; Yen EY, Singh DR, Singh RR. Trends in Systemic Sclerosis Mortality Over Forty-Eight Years, 1968–2015: A US Population-Based Study. Arthritis Care Res (Hoboken). 2021;73(10):1502–1510. doi:10.1002/acr.24411; Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. doi:10.1136/annrheumdis-2016-209909; Naidu GSRSNK, Sharma SK, Adarsh MB, et al. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a doubleblind, placebo-controlled, randomized trial. Rheumatol Int. 2020;40(2):207–216. doi:10.1007/s00296-019-04481-8; Ананьева Л.П. Современная терапия интерстициальных пневмоний, ассоциированных с системной склеродермией. Научно-практическая ревматология. 2020;58(5):520–531.; Bruni T, Varone F. The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe (Sheff). 2020;16(2):200005. doi:10.1183/20734735.0005-2020; de Figueiredo Caldas MMV, de Azevedo KPM, de França Nunes AC, et al. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis. Adv Rheumatol. 2021;61(1):15. Published 2021 Feb 27. doi:10.1186/s42358-021-00170-y; Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial [published correction appears in Lancet. 2018 Apr 7;391(10128):1356]. Lancet. 2016;387(10038):2630–2640. doi:10.1016/S0140-6736(16)00232-4; Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Respir Med. 2020 Oct;8(10):e75] [published correction appears in Lancet Respir Med. 2021 Mar;9(3):e29]. Lancet Respir Med. 2020;8(10):963–974. doi:10.1016/S2213-2600(20)30318-0; Невская Т.А., Новиков А.А., Александрова Е.Н., Мач Э.С., Запрягаева М.Н., Сперанский А.И., Гусева Н.Г., Ананьева Л.П. Клиническое значение высокочувствительного С-реактивного белка при системной склеродермии. Научно-практическая ревматология. 2007;45(4):10–17.; Cardonea nu A, Burlui AM, Macovei LA, et al. Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?. Biomedicines. 2022;10(2):318. Published 2022 Jan 29. doi:10.3390/biomedicines10020318; Ананьева ЛП. Перспективы применения тоцилизумаба при системной склеродермии. Научно-практическая ревматология. 2015;53(6):632–640.; Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?. BioDrugs. 2018;32(6):531–546. doi:10.1007/s40259-018-0320-3; Hosoya H, Derk CT. Clinically Symptomatic Pericardial Effusions in Hospitalized Systemic Sclerosis Patients: Demographics and Management. Biomed Res Int. 2018;2018:6812082. Published 2018 Jun 4. doi:10.1155/2018/6812082; Ufuk F, Çakmak P, Sağtaş E, et al. Extra-parenchymal chest HRCT findings of patients with systemic sclerosis at the time of initial diagnosis. Bezmialem Science. 2018;7(2):101–106. doi:10.14235/bs.2018.2427; Ocampo V, Haaland D, Legault K, et al. Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a pa - tient with systemic lupus erythematous. BMJ Case Rep. 2016;2016: bcr2016215423. Published 2016 Aug 8. doi:10.1136/bcr-2016-215423; Yoshida S, Takeuchi T, Sawaki H, et al. Successful treatment with tocilizumab of pericarditis associated with rheumatoid arthritis. Mod Rheumatol. 2014;24(4):677–680. doi:10.3109/14397595.2013.874733; Zacay G, Levy Y. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. Best Pract Res Clin Rheumatol. 2018;32(4):563–571. doi:10.1016/j.berh.2019.01.011; Kawaguchi Y. Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis. Journal of Scleroderma and Related Disorders. 2017;2(2):6–12. doi:10.5301/jsrd.5000258; Hernández-Sánchez J, Harlow L, Church C, et al. Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hyperten - sion. Pulm Circ. 2018;8(1):2045893217735820. doi:10.1177/2045893217735820

Verfügbarkeit: https://rsp.mediar-press.net/rsp/article/view/3230
https://doi.org/10.47360/1995-4484-2022-603-608

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6) ; Перспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6)

Autoren: E. L. Nasonov E. Feist Е. Л. Насонов et al.

Quelle: Rheumatology Science and Practice; Vol 60, No 5 (2022); 505-518 ; Научно-практическая ревматология; Vol 60, No 5 (2022); 505-518 ; 1995-4492 ; 1995-4484

Schlagwörter: олокизумаб, biological agents, interleukin-6, interleukin-6 inhibitors, tocilizumab, olokizumab, генно-инженерные биологические препараты, интерлейкин-6, ингибиторы интерлейкина-6, тоцилизумаб

Dateibeschreibung: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3215/2221; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. doi:10.1016/S0140-6736(16)30173-8; Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–196. doi:10.1016/j.immuni. 2017.02.006; McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328–2337. doi:10.1016/S0140-6736(17)31472-1; Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases – past, present and future. Nat Rev Rheumatol. 2017;13(7):443–448. doi:10.1038/nrrheum. 2017.95; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409–419.; Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637. doi:10.1136/ard.2009.123919.; Mian A, Ibrahim F, Scott DL. A systematic review of guidelines for managing rheumatoid arthritis. BMC Rheumatol. 2019;3:42. doi:10.1186/s41927-019-0090-7; Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389:2338–2348. doi:10.1016/S0140-6736(17) 31491-5; Winthrop KL, Weinblatt ME, Bathon J, Burmester GR, Mease PJ, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Ann Rheum Dis. 2020;79(1):88–93. doi:10.1136/annrheumdis-2019-216151; Schett G, McInnes IB, Neurath MF. Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. N Engl J Med. 2021;385(7):628–639. doi:10.1056/NEJMra1909094; Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457. doi:10.1038/ni.3153; Choy, E.H., De Benedetti, F., Takeuchi, T. et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020; 16, 335–345. https://doi.org/10.1038/s41584-020-0419-z; Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019;50(4):1007–1023. doi:10.1016/j.immuni.2019.03.026; Kishimoto T, Kang S. IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. Annu Rev Immunol. 2022;40:323–348. doi:10.1146/annurev-immunol-101220-023458; Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина-6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590–599.; Насонов Е.Л. Применение тоцилизумаба при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2011;49(6):46–56; Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017;77(17):1865-1879. doi:10.1007/s40265-017-0829-7.; Насонов ЕЛ, Лила АМ. Эффективность и безопасность сарилумаба (полностью человеческие моноклональные антитела к рецептору интерлейкина-6) при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2019; 57(5):564–577; Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593–1603. doi:10.2147/ DDDT.S100302; Pelechas E, Voulgari PV, Drosos AA. Sirukumab: a promising therapy for rheumatoid arthritis. Expert Opin Biol Ther. 2017;17(6):755–763. doi:10.1080/14712598.2017.1315099; Tanaka Y, Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis. 2014;73(9):1595–1597. doi:10.1136/ annrheumdis-2013-205002; Serio I, Tovoli F. Rheumatoid arthritis: new monoclonal antibodies. Drugs Today (Barc). 2018;54(3):219–230. doi:10.1358/ dot.2018.54.3.2788019; Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014;6 (3):774–82. doi:10.4161/mabs.28612; Favalli EG. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol Ther. 2020;7(3):473–516. doi:10.1007/s40744-020-00219-2; Narazaki M, Kishimoto T. Current status and prospects of IL6-targeting therapy. Exp Rev Clin Pharm. 2022;15 (5):575–592. doi:10.1080/17512433.2022.2097905; Jarlborg M, Gabay C. Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. Cytokine. 2022;149. doi: org/10.1016/j.cyto.2021.155742; Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, et al.; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–997. doi:10.1016/ S0140-6736(08)60453-5; Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609–621. doi:10.1002/art.30158; Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968–2980. doi:10.1002/art.23940; Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198–205. doi:10.1136/ ard.2010.148700; Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional diseasemodifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73(1):69–74. doi:10.1136/annrheumdis-2013-203523; Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(11):1653– 1661. doi:10.1002/acr.22384; Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antitumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–1523. doi:10.1136/ard.2008.092932; Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, et al.; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–1550. doi:10.1016/S0140- 6736(13)60250-0; Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12–19. doi:10.1007/s10165-008- 0125-1; Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88– 96. doi:10.1136/ard.2008.105197; Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016;388(10042):343–355. doi:10.1016/S0140- 6736(16)30363-4.; Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, et al. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis. 2017;76(7):1279–1284. doi:10.1136/annrheumdis-2016-210561.; Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis Rheumatol. 2015;67(6):1424–1437. doi:10.1002/art.39093; Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Res Ther. 2019;21(1):79. doi:10.1186/s13075-019-1856-4; Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, et al. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2017;69(2):277–290. doi:10.1002/ art.39944; Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallelgroup phase III trial. Ann Rheum Dis. 2017;76(5):840–847. doi:10.1136/annrheumdis-2016-210310; Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(4):469–479. doi:10.1136/annrheumdis-2021-219876; Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, et al.; CREDO2 Group. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022;387(8):715–726. doi:10.1056/NEJMoa2201302; Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Sep 15:annrheumdis-2022-222630. doi:10.1136/ard-2022-222630; Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73(9):1607–1615. doi:10.1136/annrheumdis-2013-204760; Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol. 2016;26(1):15–23. doi:10.3109/14397595.2015.1074648; Administration USFD (2020). New Drug Application (NDA): 009768, Original Approvals or Tentative Approvals. Silver Spring, MD: US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009768 (Accessed May 3, 2020).; Мазуров ВИ, Зоткин ЕГ, Гайдукова ИЗ, Иливанова ЕП, Кропотина ТВ, и соавт. Эффективность и безопасность применения левилимаба в комбинации с метотрексатом у пациентов с ревматоидным артритом: результаты II фазы исследования AURORA. Научно-практическая ревматология. 2021;59(2): 141–151.; Takeuchi T, Thorne C, Karpouzas G, Sheng S, Xu W, Rao R, Fei K, Hsu B, Tak PP. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis. 2017;76(12):2001–2008. doi:10.1136/annrheumdis-2017-211328; Aletaha D, Bingham CO 3rd, Tanaka Y, Agarwal P, Kurrasch R, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet. 2017;389(10075):1206–1217. doi:10.1016/S0140-6736(17)30401-4; Aletaha D, Kerscbaumer A, Kastrati K, Dejaco C, Dougados M, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in infkammatory conditions: an update. Ann Rheum Dis 2022. doi:10.1136/annrheumdis-2022-222784; Kastrati K, Aletaha D, Burmester GR, Chwala E, Dejaco C et al. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immunemediated inflammatory diseases. RMD Open. 2022;8:e002359. doi:10.1136/rmdopen-2022-002359; Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi:10.1136/annrheumdis-2019-216655; Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924–939. doi:10.1002/acr.24596; Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, et al.; NORD-STAR study group. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020;371:m4328. doi:10.1136/bmj.m4328; Humby F, Durez P, Buch MH, Lewis MJ, Rizvet H et al. Rituximab versus tocilizumab in anti-TNF inadequate Responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021; 397(10271):305–317. doi:10.1016/S0140-6736(20)32341-2; Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, et al. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2021;80(1): 96–102. doi:10.1136/annrheumdis-2020-217209; Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, et al.; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ. 2019;364:l67. doi:10.1136/bmj.l67; Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73(5):803–809. doi:10.1136/annrheumdis-2013-204761; Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, RubbertRoth A, Kelman A, Dimonaco S, Mitchell N. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75(6):1081–1091. doi:10.1136/ annrheumdis-2015-207628; Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75(11):1917–1923. doi:10.1136/annrheumdis-2015-208426; Teitsma XM, Marijnissen AK, Bijlsma JW, Lafeber FP, Jacobs JW. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. Arthritis Res Ther. 2016;18(1):211. doi:10.1186/s13075-016-1108-9; Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med. 2016;374(13):1243-52. doi:10.1056/NEJMoa1507247; Насонов ЕЛ, Коротаева ТВ. Ингибиторы Янус-киназ при иммуновоспалительных заболеваниях: 10 лет клинической практики в ревматологии. Научно-практическая ревматология. 2022;60(2):131-148.; Aletaha D, Smolen JS. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat Rev Rheumatol. 2019;15(11):633–634. doi:10.1038/s41584-019-0279-6; Felson DT, Lacaille D, LaValley MP, Aletaha D. Reexamining Remission Definitions in Rheumatoid Arthritis: Considering Disease Activity Score in 28 Joints, C-Reactive Protein, and Patient Global Assessment. ACR Open Rheumatol. 2022;4(2):123–127. doi:10.1002/acr2.11345; Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration. Ann Rheum Dis. 2022 Jun 15. doi:10.1136/annrheumdis-2022-222586; Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40(7):1074–1081. doi:10.3899/jrheum.121389; Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014;24(1):17–25. doi:10.3109/14397595.2013.854079; Shafran IH, Alasti F, Smolen JS, Aletaha D. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2020;79(7):874–882. doi:10.1136/annrheumdis-2019-215987; Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, et al. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis Rheumatol. 2020;72(9):1456–1466. doi:10.1002/art.41299; Gardette A, Ottaviani S, Sellam J, Berenbaum F, Lioté F, et al. Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. Clin Rheumatol. 2016;35(4):857–861. doi:10.1007/s10067-016-3183-3; Davies R, Vivekanantham A, Lunt M, et al. The effect of bodyweight on response to intravenous or subcutaneous tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2020;79:981. doi:10.1136/annrheumdis-2020-eular.4164; Nouri B, Nair N, Barton A. Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology (Oxford). 2020;59(12):3603–3610. doi:10.1093/rheumatology/keaa529; Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, et al.; SEMIRA collaborators. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet. 2020;396(10246):267–276. doi:10.1016/S0140-6736(20)30636-X; Crnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013;15(1):R1. doi:10.1186/ar4127; Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, Hidaka T, Oishi K. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362–1366. doi:10.1136/annrheumdis-2012-202658; Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2015;74(5):818–822. doi:10.1136/annrheumdis-2013-204427; Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, et al. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Ann Rheum Dis. 2021;80(6):698–706. doi:10.1136/annrheumdis-2020-219724; Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2018;57(6):997–1001. doi:10.1093/ rheumatology/key023.; Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843–1847. doi:10.1136/annrheumdis-2016-209131; Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872–1885. doi:10.1093/rheumatology/keu172; Wadström H, Frisell T, Askling J; Anti-Rheumatic Therapy in Swe den (ARTIS) Study Group. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. JAMA Intern Med. 2017;177(11):1605–1612. doi:10.1001/jamainternmed.2017.4332; Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan. Mod Rheumatol. 2016;26(5):642–650. doi:10.3109/14397595.2016.1141740.; Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76(3):504–510. doi:10.1136/annrheumdis-2016-209773; Bulte JP, Postma N, Beukema M, Inberg B, Stegeman AG, van der Hoeven H. COVID 19 and the risk of gastro-intestinal perforation: A case series and literature review. J Crit Care. 2022;67:100– 103. doi:10.1016/j.jcrc.2021.10.020; Genovese MC, Kremer JM, van Vollenhoven RF, Alten R, Scali JJ, еt al. Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. Arthritis Rheumatol. 2017;69(9):1751–1761. doi:10.1002/art.40176; McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694-702 doi:10.1136/annrheumdis-2013-204345; Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10): 1806–1812. doi:10.1136/annrheumdis-2015-207872; Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, et al. Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2020;72(1):31–40. doi:10.1002/art.41095; Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol. 2017;69(6):1154–1164. doi:10.1002/art.40084; Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2018;48(3):399–405. doi:10.1016/j.semarthrit.2018.03.012; Xie F, Yun H, Levitan EB, Muntner P, Curtis JR. Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken). 2019;71(8):1004–1018. doi:10.1002/acr.23737; Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18(1):58-68. doi:10.1038/s41569-020-0431-7; Feng Y, Ye D, Wang Z, Pan H, Lu X, Wang M, Xu Y, Yu J, Zhang J, Zhao M, Xu S, Pan W, Yin Z, Ye J, Wan J. The Role of Interleukin-6 Family Members in Cardiovascular Diseases. Front Cardiovasc Med. 2022;9:818890. doi:10.3389/fcvm.2022.818890; Ridker PM, Rane M. Interleukin-6 Signaling and AntiInterleukin-6 Therapeutics in Cardiovascular Disease. Circ Res. 2021;128(11):1728–1746. doi:10.1161/CIRCRESAHA.121.319077; Huse C, Anstensrud AK, Michelsen AE, Ueland T, Broch K, et al. Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial. EBioMedicine. 2022;80:104013. doi:10.1016/j.ebiom.2022.104013; Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, et al.; RESCUE Investigators. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060–2069. doi:10.1016/S0140- 6736(21)00520-1; Paul SK, Montvida O, Best JH, Gale S, Pethoe-Schramm A, Sarsour K. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data. Semin Arthritis Rheum. 2018;47(4):478–484. doi:10.1016/j.semarthrit.2017.08.001; Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017;56(4):541–549. doi:10.1093/rheumatology/kew370; Chen SK, Lee H, Jin Y, Liu J, Kim SC. Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus. Rheumatol Adv Pract. 2020;4(2):rkaa027. doi:10.1093/rap/rkaa027; Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, et al. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Res Ther. 2020;22(1):206. doi:10.1186/s13075- 020-02229-5; Otsuka Y, Kiyohara C, Kashiwado Y, Sawabe T, Nagano S, et al. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13(4):e0196368. doi:10.1371/journal.pone.0196368; Mori S, Yoshitama T, Hidaka T, Hirakata N, Ueki Y. Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study). Ann Rheum Dis. 2015;74(3):627–630. doi:10.1136/annrheumdis-2014-206695; Okuda Y. AA amyloidosis – Benefits and prospects of IL-6 inhibitors. Mod Rheumatol. 2019;29(2):268–274. doi:10.1080/14397595.2018.1515145; Jung JY, Kim YB, Kim JW, Suh CH, Kim HA. Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature. Medicine (Baltimore). 2021;100(32):e26843. doi:10.1097/ MD.0000000000026843; Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study. Arthritis Res Ther. 2015;17:319. doi:10.1186/s13075-015-0835-7; Strangfeld A, Meissner Y, Schäfer BL. No confirmation of increased risk of idiopathic facial nerve palsy under tocilizumab. Arthritis Rheumatol. 2019;71:2306–2308.; Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, et al.; focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963–974. doi:10.1016/S2213-2600(20)30318-0; Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, et al.; focuSSced Investigators. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021;73(7):1301–1310. doi:10.1002/art.41668; Zhang C, Zhang M, Qiu W, Ma H, Zhang X, et al.; TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391-401. doi:10.1016/S1474-4422(20)30070-3; Shin A, Park EH, Dong YH, Ha YJ, Lee YJ, et al. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study. Osteoporos Int. 2020;31(11):2131–2139. doi:10.1007/s00198- 020-05488-9; Kume K, Amano K, Yamada S, Kanazawa T, Ohta H, et al. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology (Oxford). 2014;53(5):900–903. doi:10.1093/rheumatology/ket468; Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, et al. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. PLoS One. 2017;12(11):e0188454. doi:10.1371/journal. pone.0188454; Yun H, Xie F, Beyl RN, Chen L, Lewis JD, et al. Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017;69(10):1526–1534. doi:10.1002/acr.23141; Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1078–1085. doi:10.1136/ annrheumdis-2016-210297; Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi:10.1016/j.biopha.2020.110698; McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021;9(6):643–654. doi:10.1016/ S2213-2600(21)00103-X; van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39–50. doi:10.1038/ s41591-021-01643-9; Antonov VN, Ignatova GL, Pribytkova OV, Sleptsova SS, Strebkova EA, et al. [Experience of olokizumab use in COVID-19 patients]. Ter Arkh. 2020;92(12):148–154. Russian. doi:10.26442/00403660.2 020.12.200522; Бобкова СС, Жуков ФФ, Проценко ДН, Самойленко ВВ, Тюрин ИН. Сравнительная эффективность и безопасность применения препаратов моноклональных антитед к ИЛ-6 у пациентов с новой коронавирусной инфекцией тяжелого течения. Ретроспективное когортное исследование. Вестник интенсивной терапии им. А.И. Салтанова. 2021;1:69–76. doi:10.21320/1818-474X-2021-1-69-76; Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med. 2020;217(5):e20190347. doi:10.1084/jem.20190347.; Гордеев АВ, Галушко ЕА, Насонов ЕЛ. Концепция мультиморбидности в ревматологической практике. Научнопрактическая ревматология. 2014;52(4):362-365.; Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med. 2021;10(3):509. doi:10.3390/ jcm10030509; Hill J, Harrison J, Christian D, Reed J, Clegg A, Duffield SJ, Goodson N, Marson T. The prevalence of comorbidity in rheumatoid arthritis: a systematic review and meta-analysis. Br J Community Nurs. 2022;27(5):232–241. doi:10.12968/bjcn.2022.27.5.232; Ting EY, Yang AC, Tsai SJ. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194. doi:10.3390/ ijms21062194; Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин-6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318–327.; Roohi E, Jaafari N, Hashemian F. On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos? J Neuroinflammation. 2021;18(1):45. doi:10.1186/s12974-021- 02100-7; Sebba A. Pain: A Review of Interleukin-6 and Its Roles in the Pain of Rheumatoid Arthritis. Open Access Rheumatol. 2021;13:31–43. doi:10.2147/OARRR.S291388; Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev. 2021;8(8):CD013484. doi:10.1002/14651858.CD013484.pub2. Update in: Cochrane Database Syst Rev. 2022;5:CD013484.; Conway R, Putman MS, Mackie SL. Benchmarking tocilizumab use for giant cell arteritis. Rheumatol Adv Pract. 2022;6(2):rkac037. doi:10.1093/rap/rkac037; Бекетова ТВ, Ушакова МА, Никишина НЮ, ХелковскаяСергеева АН, Николаева ЕВ, и соавт. Опыт применения ингибитора интерлейкина-6 тоцилизумаба для лечения гигантоклеточного артериита с тяжелой коморбидной патологией. Научно-практическая ревматология. 2018;56(2):228– 234.; Li H, Shuai Z. Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review. Heart Vessels. 2022;37(5):884–894. doi:10.1007/s00380-021-01981-1; Akioka S. Interleukin-6 in juvenile idiopathic arthritis. Mod Rheumatol. 2019;29(2):275–286. doi:10.1080/14397595.2019. 1574697; Castañeda S, Martínez-Quintanilla D, Martín-Varillas JL, García-Castañeda N, Atienza-Mateo B, et al. Tocilizumab for the treatment of adult-onset Still’s disease. Expert Opin Biol Ther. 2019;19(4):273–286. doi:10.1080/14712598.2019.1590334; Koga T, Kawakami A. Interleukin-6 inhibition in the treatment of autoinflammatory diseases. Front Immunol. 2022;13:956795. doi:10.3389/fimmu.2022.956795; Si S, Teachey DT. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. Ther Clin Risk Manag. 2020;16:705–714. doi:10.2147/TCRM.S223468; Zhang J, Luo W, Miao C, Zhong J. Hypercatabolism and Anticatabolic Therapies in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome. Front Nutr. 2022; 9:941097. doi:10.3389/fnut.2022.941097

Verfügbarkeit: https://rsp.mediar-press.net/rsp/article/view/3215
https://doi.org/10.47360/1995-4484-2022-505-518

Rationality of routine clinical use of olokizumab in COVID-19

Autoren: V. M. Tsvetov A. V. Matveev D. A. Sychev

Quelle: Качественная клиническая практика, Vol 0, Iss 4S, Pp 68-70 (2020)

Schlagwörter: RS1-441, 0301 basic medicine, 0303 health sciences, 03 medical and health sciences, Pharmacy and materia medica, covid-19, Medical technology, коронавирус, R855-855.5, олокизумаб, 3. Good health

Zugangs-URL: https://www.clinvest.ru/jour/article/download/530/538
https://doaj.org/article/1b429c37cc9a4d7cbc00aad081552c14
https://www.clinvest.ru/jour/article/download/530/538
https://www.clinvest.ru/jour/article/view/530
https://cyberleninka.ru/article/n/tselesoobraznost-rutinnogo-primeneniya-preparata-olokizumab-pri-covid-19/pdf
https://cyberleninka.ru/article/n/tselesoobraznost-rutinnogo-primeneniya-preparata-olokizumab-pri-covid-19

The effect of olokizumab on rheumatoid arthritis patient’s reported outcomes: results of a double-blind randomized placebo-controlled multicenter phase III trial (CREDO 1) ; Влияние олокизумаба на исходы, оцениваемые пациентом с ревматоидным артритом: результаты двойного слепого рандомизированного плацебо-контролируемого многоцентрового исследования III фазы (CREDO 1)

Autoren: E. L. Nasonov T. A. Lisitsyna E. V. Zonova et al.

Weitere Verfasser: E. L. Nasonov T. A. Lisitsyna E. V. Zonova et al.

Quelle: Rheumatology Science and Practice; Vol 59, No 1 (2021); 62-69 ; Научно-практическая ревматология; Vol 59, No 1 (2021); 62-69 ; 1995-4492 ; 1995-4484

Schlagwörter: оцениваемые пациентом, IL-6 inhibitors, olokizumab, CREDO 1, patient’s reported outcomes, ингибиторы ИЛ-6, олокизумаб, исходы

Dateibeschreibung: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2991/2060; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. doi:10.1016/S0140-6736(16)30173-8; Ревматология: Российские клинические рекомендации. Под ред. ЕЛ Насонова. М.: ГЭОТАР-Медиа;2017:464.; Kingsley G, Scott IC, Scott DL. Quality of life and the outcome of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25(4):585–606. doi:10.1016/j.berh.2011.10.003; An J, Nyarko E, Hamad MA. Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis. Clin Rheumatol. 2019;38(10):2717–2726. doi:10.1007/s10067-019-04613-2; Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36(6):729–740. doi:10.1002/art.1780360601; Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res. 1992;5(3):119–129. doi:10.1002/art.1790050303; Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2008;14(4):234– 254.; Van Tuyl LH, Michaud K. Patient-reported outcomes in rheumatoid arthritis. Rheum Dis Clin North Am. 2016;42(2):219–237. doi:10.1016/j.rdc.2016.01.010; Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis – progress at OMERACT 7. J Rheumatol. 2005;32:2250–2256.; Генно-инженерные биологические препараты в лечении ревматоидного артрита. Под ред. ЕЛ Насонова. М.: ИМА-ПРЕСС;2013.; Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590–599. doi:10.14412/1995-4484-2017-590-599; Narazaki M, Tanaka T, Kishimoto T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol. 2017;13(6):535–551. doi:10.1080/1744666X.2017.1295850; Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: What’s the difference? BioDrugs. 2018;32(6):531–546. doi:10.1007/s40259-018-0320-3; Kretsos K, Jullion A, Zamacona M, Harari O, Shaw S, Boulanger B, et al. Model-based optimal design and execution of the first-inpatient trial of the anti-IL-6, olokizumab. CPT Pharmacometrics Syst Pharmacol. 2014;3(6):e119. doi:10.1038/psp.2014.17; Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014;3(5):388–395. doi:10.1002/cpdd.121; Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73(9):1607–1615. doi:10.1136/annrheumdis-2013-204760; Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol. 2016;26(1):15–23. doi:10.3109/14397595.2015.1074648; Nasonov E, Fatenejad S, Korneva E, Krechikova D, Maslyansky A, Plaksina T, et al. Safety and efficacy of olokizumab in a phase III trial of patients with moderately to severely active rheumatoid arthritis inadequately controlled by methotrexate – CREDO1 study [abstract]. Arthritis Rheumatol. 2019;71(suppl 10). URL: https://acrabstracts.org/abstract/safety-and-efficacy-of-o-lokizumab-in-a-phase-iii-trial-of-patients-with-moderately-to-se-verely-active-rheumatoid-arthritis-inadequately-controlled-by-methotrexate-credo1-study (accessed July 7, 2020).; Nasonov E, Stoilov R, Tyabut T on behalf of Saeed Fatenejad (United States of America), Krechikova D., Korneva E., Maslyansky A., et al. OP0021 olokizumab, monoclonal antibody against IL6, in patients with moderately to severely active rheumatoid arthritis inadequately controlled by methotrexate: Efficacy and safety results of phase III CREDO-1 study. Annals of the Rheumatic Diseases. 2020;79:16–17. doi:10.1136/annrheumdis-2020-eular.1688; Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S14–36. doi:10.1002/acr.20621; Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):811–819.; Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H. Validity of Euroqol – a generic health status instrument – in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol. 1994;33(7):655–662. doi:10.1093/rheumatology/33.7.655; Ware JE, Kosinski M, Keller SK: SF-36 physical and mental health summary scales: A user’s manual. Boston: New England Medical Center, The Health Institute;1994.; Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137–145.; Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–48.; Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S100–108.; Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, et al. It’s good to feel better but it’s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol. 2011;38:1720–1727.; Амирджанова ВН, Горячев ДВ, Коршунов НИ, Ребров АП, Сороцкая В.Н. Популяционные показатели качества жизни по опроснику SF-36 (результаты многоцентрового исследования качества жизни «МИРАЖ»). Научно-практическая ревматология. 2008;46(1):36–48. doi:10.14412/1995-4484-2008-852; Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol. 1993;20:557–560.; Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics. 2004;22:27–38.; Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123–130. doi:10.1016/j.semarthrit.2014.05.001; Heaney A, Stepanous J, Rouse M, McKenna SP. A review of the psychometric properties and use of the Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) in clinical research. Curr Rheumatol Rev. 2017;13(3):197–205. doi:10.2174/1573396313666170615092324; Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–345. doi:10.1038/s41584-020-0419-z; Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). 2018;57(11):1885–1895. doi:10.1093/rheumatology/kex391; Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин 6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318–327. doi:10.14412/1995-4484-2019-318-327; Matcham F, Galloway J, Hotopf M, Roberts E, Scott IC, Steer S, et al. The impact of targeted rheumatoid arthritis pharmacologic treatment on mental health: A systematic review and network meta-analysis. Arthritis Rheumatol. 2018;70(9):1377–1391. doi:10.1002/art.40565; Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, et al. Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of life outcomes in patients with rheumatoid arthritis. RMD Open. 2018;4:e000602. doi:10.1136/rmdopen-2017-000602; Sebba A, Han J, Mohan S. Pain and other patient-reported outcomes in patients with rheumatoid arthritis who did or did not achieve treatment response based on improvement in swollen joints in tocilizumab clinical trials [abstract]. Arthritis Rheumatol. 2020; 72(suppl 10). URL: https://acrabstracts.org/abstract/pain-and-other-patient-reported-outcomes-in-patients-with-rheumatoid-arthritis-who-did-or-did-not-achieve-treatment-response-based-on-improvement-in-swollen-joints-in-tocilizumab-clinical-trials/ (accessed July 7, 2020).; Crotti C, Biggioggero M, Becciolini A, Favalli EG. Sarilumab: patient-reported outcomes in rheumatoid arthritis. Patient Relat Outcome Meas. 2018;9:275–284. doi:10.2147/PROM.S147286; Насонов ЕЛ, Лила АМ. Эффективность и безопасность сарилумаба (полностью человеческие моноклональные антитела к рецептору интерлейкина 6) при ревматоидном артрите: новые данные. Научно-практическая ревматология. 2019;57(5):564–577. doi:10.14412/1995-4484-2019-564-57; Atzeni F, Nucera V, Masala IF, Sarzi-Puttini P, Bonitta G. Il-6 involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab. Pharmacol Res. 2019;149:104402. doi:10.1016/j.phrs.2019.104402; Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–68. doi:10.1136/annrheumdis-2013-204223; Nerurkar L, Siebert S, McInnes IB, Cavanagh J. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry. 2019;6(2):164–173. doi:10.1016/S2215-0366(18)30255-4; Zhou AJ, Lee Y, Salvadore G, Hsu B, Fonseka TM, Kennedy SH, et al. Sirukumab: A potential treatment for mood disorders? Adv Ther. 2017;34:78–90. doi:10.1007/s12325-016-0455-x; Brietzke E, Scheinberg M, Lafer B. Therapeutic potential of interleukin-6 antagonism in bipolar disorder. Medical Hypotheses. 2011;76(1):21–23. doi:10.1016/j.mehy.2010.08.021; Miller BJ, Dias JK, Lemos HP, Buckley PF. An open-label, pilot trial of adjunctive tocilizumab in schizophrenia. J Clin Psychiatry. 2016;77:275–276. doi:10.4088/JCP.15l09920; Miller BJ, Buckley PF. Monoclonal antibody immunotherapy in psychiatric disorders. Lancet Psychiatry. 2017;4(1):13–15. doi:10.1016/S2215-0366(16)30366-2

Verfügbarkeit: https://rsp.mediar-press.net/rsp/article/view/2991
https://doi.org/10.47360/1995-4484-2021-62-69

Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm ; Оценка экономического эффекта применения биологической терапии у пациентов с тяжелым течением COVID-19 и развитием цитокинового шторма

Autoren: M. Yu. Frolov A. S. Salasyuk V. A. Rogov et al.

Weitere Verfasser: M. Yu. Frolov A. S. Salasyuk V. A. Rogov et al.

Quelle: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 13, No 4 (2020); 377-387 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 13, No 4 (2020); 377-387 ; 2070-4933 ; 2070-4909

Schlagwörter: левилимаб, cytokine storm, cost of disease, olokizumab, tocilizumab, levilimab, цитокиновый шторм, стоимость болезни, олокизумаб, тоцилизумаб

Dateibeschreibung: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/445/347; Andersen K. G. et al. The proximal origin of SARS-CoV-2. Nature medicine. 2020; 26 (4): 450-452. https://doi.org/10.1038/s41591-020-0820-9.; Hu B. et al. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology. 2020; 1-14. https://doi.org/10.1038/s41579-020-00459-7.; Онлайн статистика коронавируса Covid-19 в России [Электронный ресурс] URL: https://coronavirus-monitor.ru/coronavirus-v-rossii/. Дата обращения: 10.09.2020.; Гриневич В.Б., Губонина И.В., Дощицин В.Л., Котовская Ю.В., Кравчук Ю.А., Педь В.И., Сас Е.И., Сыров А.В., Тарасов А.В., Тарзиманова А.И., Ткачева О.Н., Трухан Д.И. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020;19 (4): 2630. https://doi.org/10.15829/1728-8800-2020-2630.; Violi F. et al. Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge. Thrombosis and haemostasis. 2020; 120 (6): 949. https://doi.org/10.1055/s-0040-1710317.; Wu Z., McGoogan J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020; 323: 13. https://doi.org/10.1001/jama.2020.2648.; Lazzerini M., Putoto G. COVID-19 in Italy: momentous decisions and many uncertainties. The Lancet Global Health. 2020; 8 (5): e641-e642. https://doi.org/10.1016/S2214-109X(20)30110-8.; Moore J. B., June C. H. Cytokine release syndrome in severe COVID-19. Science. 2020; 368 (6490): 473-474. https://doi.org/10.1126/science.abb8925.; Lu S. et al. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis. Annals of translational medicine. 2020; 8 (10). https://doi.org/10.21037/atm-20-3307.; Conticini E. et al. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs Annals of the Rheumatic Diseases. 2020; https://doi.org/10.1136/annrheumdis-2020-217681.; Камкин Е. Г. и др. Профилактика, диагностика и лечение но вой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Версия 9 (26.10.2020). М.: Министерство Здравоохранения Российской Федерации [Электронный ресурс] URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/MP_COVID-19_%28v.9%29.pdf?1603730062. Дата обращения: 11.11.2020.; Li H. et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. The Lancet. 2020; 395 (10235): 1517-1520. https://doi.org/10.1016/S0140-6736(20)30920-X; Cardenas G. et al. Role of Systemic and Nasal Glucocorticoid Treatment in the Regulation of the Inflammatory Response in Patients with Sars-Cov-2 Infection. Archives of Medical Research. 2020; https://doi.org/10.1016/j.arcmed.2020.10.014; Aziz M., Fatima R., Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. Journal of Medical Virology. 2020. 92 (11): 2283-2285. https://doi.org/10.1002/jmv.25948.; Liu B. et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Journal of Autoimmunity. 2020; 111: 102452. https://doi.org/10.1016/j.jaut.2020.102452.; Ап update on the phase I IICOVACTAttial ofActemraaRoActemra i nhospi-talised patients with severe COVID-19 associated pneumonia [Электронный ресурс] URL: https://www.roche.cor/redia/releases/red-cor-2020-07-29.htr. Дата обращения: 11.11.2020.; Guaraldi G. et al. Tocilizurab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology. 2020; 2 (8): e474-e484. https://doi.org/10.1016/S2665-9913(20)30173-9.; Della-Torre E. et al. Interleukin-6 blockade with sarilurab in severe COVID-19 pneuronia with systeric hyperinflarration: an open-label cohort study. Annals of the rheumatic diseases. 2020; 79: 1277-1285. http://dx.doi.org/10.1136/annrheurdis-2020-218122.; Russell B. et al. cssociations between irrune-suppressive and stirulating drugs and novel COVID-19—a systematic rrevew oo currant eeideecc. Ecancermedicalscience. 2020; 14. http://dx.doi.org/10.3332/ecancer.2020.1022.; Caracciolo M. et al. Case Report: Canakinumab for the Treatment of a patient with COVID-19 ccute Respiratory Distress Syndrome. Frontiers in Immunology. 2020; 11: 1942. http://dx.doi.org/10.3389/fimmu.2020.01942.; Насонов Е.Л., Лила А.М. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017; 55 (6): 590-599.; Артлегиа (олокизумаб). Инструкция по медицинскому применению лекарственного препарата. ЛП-006218 Государственный реестр лекарственных средств Министерства здравоохранения РФ [Электронный ресурс] URL: https://grls.rosminzdrai.ru/grls.aspx/. Дата обращения: 03.12.2020.; Новая коронавирусная инфекция (COVID-19): этиология, эпидемиология, клиника, диагностика, лечение и профилактика. М. 2020; 71 с.; Клыпа Т. В. и др. Клиническая характеристика пациентов с COVID-19, поступающих в отделение интенсивной терапии. предикторы тяжелого течения. Клиническая практика. 2020; 11 (2): 6-20.; Manson J. J. et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospectiie longitudinal cohort study. The Lancet Rheumatology. 2020; https://doi.org/10.1016/S2665-9913(20)30275-7.; Ramiro S. et al. Historically controlled comparison of glucocorticoids with or without tocilizumab iersus supportiie care only in patients with COVID-19-associated cytokine storm syndrome: results of the chiC study. Annals of the rheumatic diseases. 2020; 79 (9): 1143-1151. http://dx.doi.org/10.1136/annrheumdis-2020-218479.; WHO R&D Blueprint. Noiel coronaiirus, outline of designs for experimental therapeutics, 2020. [Электронный ресурс] URL: https://apps.who.int/iris/bitstream/handle/10665/330695/WHO-HEO-RDBlueprintnCoV-2020.5-eng.pdf?sequence=1&iscllowed=y. Дата обращения: 03.12.2020.; Камкин Е. Г. и др. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Краткая версия. [Электронный ресурс] URL: https://стoпкopoнaвupyc.рф/ai/doc/204/attach/COVID_pocketbook_v6.pdf. Дата обращения: 03.12.2020.; Данные о предельных размерах оптовых надбавок и предельных размерах розничных надбавок к ценам на жизненно необходимые и важнейшие лекарственные препараты, установленные в субъектах Российской Федерации (данные на 10 февраля 2020) [Электронный ресурс] URL: https://fas.gov.ru/documents/686367. Дата обращения: 10.02.2020.; Nasonov E., Fatenejad S., Korneva E., Krechikova D., Maslyansky c., Plaksina T., Stanislav M., Stoilov R., Tyabut T., Yakushin S., Zonova E., Genovese M.C. Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely cctive, Rheumatoid crthritis Inadequately Controlled by Methotrexate - CREDO1 Study [abstract]. Arthritis Rheumatol. 2019; 71 (10).; Nasonov E., Stoilov R., Tyabut T., Genovese M.C. Olokizumab, Monoclonal cntibody cgainst IL6, in Patients with Moderately to Severely cctive Rheumatoid crthritis Inadequately Controlled by Methotrexate: Efficacy and Safety Results of Phase III CREDO-1 Study. EU-LcR2020, abstract book, OP0021.; Фармакоэкономика для вузов: учеб. пособие / Р. И. Ягудина, А. Ю. Куликов, В. Г. Серпик. Ростов-на-Дону. 2017; 237.; Федеральная служба государственной статистики. Валовой внутренний продукт, годовые данные. [Электронный ресурс] URL: https://www.gks.ru/storage/mediabank/tab1(2).htm. Дата обращения: 10.02.2020.; Федеральная служба государственной статистики. Численность постоянного населения в среднем за год. [Электронный ресурс] URL: https://showdntn.gks.ru/report/278930/. Дата обращения: 10.02.2020.; https://www.pharmacoeconomics.ru/jour/article/view/445

Verfügbarkeit: https://www.pharmacoeconomics.ru/jour/article/view/445
https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.076

Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real clinical practice in Kazakhstan

Autoren: G. A. Togizbayev D. I. Parpiyeva D. A. Maksot

Quelle: Современная ревматология, Vol 0, Iss 0 (2020)

Schlagwörter: ревматоидный артрит, олокизумаб, ингибиторы ил-6, эффективность, безопасность, Medicine

Dateibeschreibung: electronic resource

Relation: https://mrj.ima-press.net/mrj/article/view/1732; https://doaj.org/toc/1996-7012; https://doaj.org/toc/2310-158X

Zugangs-URL: https://doaj.org/article/c8bb6939dfe24ce9b538ef35c3b23faf

ФАРМАКОЭПИДЕМИОЛОГИЧЕСКИЙ АНАЛИЗ СТРУКТУРЫ НАЗНАЧЕНИЙ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ У ПАЦИЕНТОВ С ПОДТВЕРЖДЁННЫМ ПЦР-ТЕСТИРОВАНИЕМ НА COVID-19

Autoren: Абрамова А.А. Киселев Н.А. Останина Т.В.

Quelle: Актуальные проблемы экспериментальной и клинической медицины

Schlagwörter: covid-19, моноклональные антитела, структура фармакотерапии, ингибитор ИЛ-6, ингибиторы Янус-киназы, левилимаб, олокизумаб, тоцилизумаб

Relation: https://repository.rudn.ru/records/article/record/104268/

Verfügbarkeit: https://repository.rudn.ru/records/article/record/104268/